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Introduction 
8 CHAPTER 1 
Rheumatoid arthritis 
Rheumatoid arthritis is a illness characterized by a chronic polyarthritis, often involving 
hands and wrists. Serological abnormalities (e.g. rheumatoid factor) occur and the 
inflammatory process generally leads to clinically evident joint damage. Its cause(s) are 
still unidentified. For research purposes classification criteria have been made to 
delimitate this disease from other rheumatic disorders [l]. It is a common disease, its 
prevalence is about 1-2%, and occurs almost two times more often in women. The peak 
incidence of the disease occurs between the ages 40 and 55, but both age extremes are 
represented. On average the patient will thus have to live with this disease for about 30 
years. Because curative therapy is not (yet) available, it must cover the same time-span 
The clinical manifestations of the disease vary from a synovitis of small and large 
joints and tendonsheaths to extra-articular features as nodules and vasculitis, and 
sequelae like amyloidosis. It is capricious in its prognosis. Where a minority of patients 
will have a relatively mild non-destructive synovitis of limited duration, most will have 
an exacerbating and remitting arthritis ultimately leading to destruction of joints and 
surrounding structures. This structural damage to the joints can be demonstrated 
radiographically already early in the course of the disease [2]. Due to extra-articular 
pathology, various organs, e.g. lungs and kidneys, can be affected. Rheumatoid arthritis 
not only causes substantial morbidity but probably also a decrease in lifespan [3][4]. 
Pharmacotherapy of rheumatoid arthritis 
The treatment of the patient suffering from rheumatoid arthritis consists of drugs, 
surgery, occupational and physical therapy combined with psychosocial support. The 
principal therapeutic modality directed at the inflammatory process is the 
pharmacological one. Its goal is to have a maximal impact on symptoms and prognosis 
with minimal toxic effects. Drugs against rheumatoid arthritis can be arbitrarily divided 
in first and second line agents. Non-steroidal anti-inflammatory agents (NSAIDs) are 
the first line agents, second line agents are known by some other names: disease 
modifying antirheumatic drugs (DMARDs) or slow acting antirheumatic drugs, 
indicating the intended influence on the rheumatoid proces or their onset of action. 
Corticosteroids, although being one of the older antirheumatic drugs, have no defined 
place in this spectrum yet. The first line drugs are complementary to the second line 
agents: they are supposed to act immediately (within days) on the symptoms and to 
have no influence on the structural damage caused by the inflammatory proces. As the 
name "first line" suggest, they are supposed to be employed before other agents are 
given and only if they fail, other drugs should be given. Also, supposedly these drugs 
have less side effects than the second line drugs. These alleged properties of first and 
second line drugs are only very partially true: NSAIDs are not as harmless as is 
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suggested by their first place in the therapy. Especially gastro-intestinal adverse events 
are a problem, both in quantity and in seriousness. Often, they do not provide sufficient 
alleviation of pain and stiffness. The "DMARDs" are doubted by several authors in 
their capacity to fulfil the promise of real change of prognosis [5][6]. In view of these 
problems, other ways of categorization of antirheumatic drugs have been proposed. 
One of these classifications is to divide agents in symptom-modifying antirheumatic 
drugs and disease-controlling antirheumatic therapy, the latter having real impact on 
the structural damage and fundamentally altering the underlying disease proces. The 
second line drugs are used one after another m clinical practice. This sequential use of 
single DMARD therapy has an impact on prognosis [7]. However, it is not the ultimate 
answer: DMARD "survival-curves" show that this therapy can be ineffective from the 
start or a secondary drug resistance can emerge, or toxicity is precluding further use of 
the drug involved. Only 10-60% of the patients will continue to take the initially 
prescribed second-line antirheumatic drag after a period of 5 years [8][9]. 
Although there is a continuous search for and sometimes a discovery of new 
antirheumatic drugs, e g. biological agents with influence on important inflammatory 
mediators such as cytokines, they are not available at the present for non-experimental 
use. In view of the shortcomings of the single sequentially used drugs as described 
above, other ways of using these drugs have been sought, altering the sequence and 
timing of use or to combine them [10][ll][l2][l3]. The rationale of combining, which 
drugs to combine and how to use combinations, and an overview of preliminary 
experience is given in Chapter 2. 
Sulphasalazine and methotrexate. 
The combination of antirheumatic drugs described in this thesis are sulphasalazine and 
methotrexate. The goal of combining is to have an optimal efficacy in view of the 
disappointing results of single therapy. Since both drugs have shown to have a 
relatively quick onset of action and superior influence on both symptoms and on 
disease related outcome (radiographical damage) compared to other drugs [14][15][16], 
these were chosen to be combined. 
Sulphasalazine (SSZ) is a compound drug with a sulphonamide component and a 
salicylic part covalently joined by an azo-bond; sahcylazosulphapyridine. In the gut the 
largest part (70-90%) of the ingested molecules are split by bacterial enzymes in 
sulphapyndine and 5-ammo salicylic acid. The sulphapyndine moiety is rapidly 
absorbed and metabolized by acetylation and glucuromdation after which it is excreted 
m the urine. The 5-ammosahcyl part is poorly absorbed and excreted in the faeces. SSZ 
and sulphapyndine have antibacterial effects but the lack of relation between changes 
in the bacterial flora and the clinical response [17], and the fact that other 
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sulphonamides do not have a antirheumatic effect [18], argue against relevance of these 
antimicrobial properties. The effects of SSZ and its metabolites on folic acid 
metabolism are variable and only studied in vitro [19]. Although the drug seems to have 
influence on the absorption of folic acid in inflammatory bowel disease [20], in 
rheumatoid arthritis patients this effect could not be demonstrated [21]. SSZ and/or its 
metabolites have multiple antiinflammatory and immunomodulatory effects, for 
example influence on prostaglandin and leukotriene metabolism, on humoral (B-cells) 
and on cellular (T-cells and cytokines of macrophage- and T-cell origin) immunity, as 
was reviewed recently [22]. Clinically, SSZ is an antirheumatic agent unfolding its 
action in 2-12 weeks after start. As stated above, it is an important second-line agent, 
with an efficacy which is equal or better than others also recently reviewed [23]. A 
problem with SSZ, as it is with most if not all antirheumatic drugs, is the secondary 
resistance, i.e. loss of efficacy after an initially well suppressed disease activity. 
Methotrexate (MTX, 4-amino-4-deoxy-N10-methylpteroylglutarnic acid) is a folic 
acid analogue and an important antirheumatic drug which clinical use has emerged 
some fifteen years ago. Taken orally the bioavailabilty is about 70-80%. The maximum 
concentration is reached in ± 2 hours. The drug is eliminated mainly by the kidney by 
glomerular filtration and tubular excretion [24]. Biliary excretion contributes only for a 
small part to the elimination [25]. After ± 48 hours no MTX is detectable in serum in 
the average patient. It has various metabolites of which 7-OH-MTX is the principal one 
with some pharmacological action. 
The mode of action of MTX in RA is unknown. By inhibiting the tetrahydrofolic 
acid dependent metabolic pathways it can have an effect on nucleotid-synthesis, thus 
exerting a cytostatic effect. Another consequence of tetrahydrofolic acid antagonism is 
the blocking of conversion of certain aminoacids in others (serine - glycine, 
homocysteine - methionine) which at its turn influences protein metabolism. All 
metabolic steps involve methylation, which also plays a role in the formation of 
moieties involved in inflammation, like polyamines and adenosine [26][27]. 
A direct cytostatic effect does not seem to explain why MTX works in RA. An anti-
inflammatory effect [28], perhaps mediated by interference with protein metabolism, 
may account for the effect. MTX appears to have an effect on cytokine-pathways [29]. 
Adverse drug reactions to MTX are responsible for termination of treatment in about 
35% of the RA-patients using this drug [30]. Mostly these are gastro-intestinal 
problems, varying from slight nausea to elevation of the concentration of hepatic 
enzymes in serum. Frank cirrhosis unequivocally attributable to MTX has not been 
described to occur in RA-patients. Still liver cirrhosis due to MTX did occur in patients 
with psoriasis, possibly due to the higher doses used in that disease. Severe pulmonary 
toxicity also is a serious but relatively seldom occurring event. Weinblatt reviewed 
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MTX-use in RA and concluded that MTX is an effective drug also compared to other 
slow acting antirheumatic agents and that its "survival" in clinical practice compares 
favorably to others [31]. 
Phases of drug development. 
The process of the development of pharmacotherapeutic agents passes through four 
phases after it has been tested in vitro and in several species of animals [32]. The first 
phase is the investigation of safety, biological effects, metabolism and kinetics in 
healthy volunteers. In the second phase the therapeutic efficacy, dose range, kinetics 
and metabolism is studied, mostly in smaller samples of patients. The balance of 
efficacy and safety is studied in the third phase in trials of larger sample size. After 
introduction on the market phase four commences, adverse drug reactions, drug-
utilization and additional indications are studied. This phase is also called the 
postmarketing surveillance. 
This study of the combination of SSZ and MTX was done with the above mentioned 
phases of drug-development in mind. Since there was ample knowledge on the single 
agents, a formal phase 1 was not gone through, although various biological effects of 
the combination were studied: the influence on cytokines and on folic acid-one carbon 
metabolism. Parallel to the study of single drug pharmacokinetics, the interaction 
between the two components was studied in a group of patients which was also studied 
for clinical efficacy, thus forming a sort of phase 2. In phase 3 a larger clinical trial was 
performed studying the efficacy and toxicity. 
Aim and outline of the thesis 
The aim of this thesis is to evaluate the place of a specific combination of second line 
antirheumatic drugs: sulphasalazine and methotrexate, in the pharmacological 
treatment of rheumatoid arthritis. To reach this aim the pharmacokinetic interaction, the 
influence on mediators of inflammation and on folate and folate dependent metabolism, 
and the clinical effects of this combination have been studied. 
Chapter 1 is this introduction. 
In Chapter 2 the reasons why to use combinations, the selection of combinations and 
an overview of combinations used to treat rheumatoid arthritis are given, with the 
emphasis on combinations containing SSZ and MTX. 
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In Chapter 3 the possible influence of SSZ on the pharmacokinetics of MTX and vice 
versa, and the relationship between pharmacokinetic variables and clinical effects is 
studied. 
In Chapter 4 the effects of SSZ, MTX and the combination of both on circulating 
cytokines and their production is depicted. 
Chapter 5 describes the impact of the combination and its individual components on 
the blood-levels of folic acid and of an important product of methylation linked with 
the metabolism of folic acid: homocysteine. 
In Chapter 6 the results of a clinical trial of the combination in the treatment of 
rheumatoid arthritis patients who have insufficient response to SSZ are given. 
In Chapter 7 a trial to compare the combination with the single drugs in patients with 
rheumatoid arthritis in an very early phase of their disease is described. 
Chapter 8 is a summary and discussion of the preceding chapters. 
Chapter 9 includes a dutch summary, acknowledgements and a curriculum vitae of the 
author. 
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CHAPTER 2 
Combination of Second Line Antirheumatic Drugs, 
with the Emphasis 
on Sulphasalazine and Methotrexate 
Cees J. Haagsma and Piet L.C.M, van Riel 
Abstract: Single drug therapy often is not satisfactory in the treatment of chronic arthritis. The 
combination of second line antirheumatic drugs is therefore increasingly employed. Various 
strategies of combining drugs can be used, starting with combinations or adding agents in case 
of insufficient effect of single therapy. Effective combinations have to be found empirically 
since lack of knowledge about pharmacodynamics and pharmacokinetics often hinders rational 
choices. Few controlled studies on combinations of second line antirheumatic drugs exist, 
results suggesting very moderately increased efficacy and increased toxicity. Recently, results 
of combinations, mainly with methotrexate, became available. Combining this agent with 
azathioprine did not offer advantages. Cyclosporine added to insufficiently effective 
methotrexate possibly has some value and antimalarials combined with methotrexate may be 
beneficial regarding effectivity and/or toxicity. Methotrexate added to insufficiently effective 
sulphasalazine seems to be better than methotrexate alone, although this combination when 
used from the start of the therapy was disappointing. Triple therapy of the latter combination 
together with hydroxychloroquine turned out to be superior to single methotrexate and to the 
combination of sulphasalazine and hydroxychloroquine. Surprisingly, the toxicity of these 
combinations mostly was comparable to single therapy. In conclusion, combinations of second 
line antirheumatic drugs have a role, although not yet clearly defined, in the therapy of chronic 
arthritis. 
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Introduction 
The therapy of rheumatoid arthritis (RA) in the initial phases of the disease consists 
mainly of drags. There are indications that considerable joint damage already occurs m 
the initial stages, as was detected by radiographical analysis [1]. It seems therefore 
important to start disease modifying antirheumatic drugs (DMARDs) soon after the 
diagnosis has been established. This can beneficially alter the clinical course as was 
mdicated by a recent study in early RA [2]. Single DMARD therapy however, is not the 
ultimate answer: DMARD "survival-curves" show that this therapy can be ineffective 
from the start or a secondary drug resistance can emerge, or toxicity is precluding 
further use of the drug involved [3][4]. To tackle these difficulties, strategies were 
proposed to leave the current practice of using antirheumatic drugs sequentially and 
hierarchically, starting with the least toxic (and often the least effective) one [5][6][7][8]. 
One of these proposals is to combine DMARDs [9][10]. 
Motives for the use of combination therapy 
• Using drugs singly do not provide satisfactory results. 
• The mechanism of action of individual drugs can be different, so combinations can 
lead to synergism or at least additive effects. 
• Using drugs with different toxicity profiles in combination may have a better 
efficacy/toxicity ratio, allowing lower doses. 
• It may take several drugs to find an effective one if DMARDs are tried one after 
another. This may delay effective treatment. 
• Residual effects of previous DMARDs are lost, starting the next single-agent 
therapy and stopping the previous one. 
Selection of specific combinations 
In his article [ll] concerning why to combine which antirheumatic drugs, Fürst 
suggested to use knowledge of pharmacodynamics and pharmacokinetics to optimalize 
the choice of specific combinations. In matrices considering mechanisms of action, 
kinetics and toxicity this method of selection was specified. Although such an effort to 
rationally put together various DMARDs is in principle the obvious way, it is hampered 
by a lack of knowledge of the pathogenesis of (rheumatoid) arthritis and whether 
measured effects of DMARDs really matter in terms of clinical effectivity and toxicity. 
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This is illustrated by studies showing no advantage of addition of oral gold to 
methotrexate [12], no extra beneficial effects of the combination of sulphasalazine and 
hydroxychloroquine over the single components [13] and maybe some increased 
efficacy but also increased toxicity (hepatic enzymes) of methotrexate and chloroquine 
[14] in randomized trials. This is contrary to the suggested choices resulting from the 
matrices given by Fürst. Thus, although rational choices are appealing, no solid data 
exist now by which such choices can be made. The empirical approach of trial (and 
error) is as yet the only way to find useful combinations. 
Strategies of combining second-line antirheumatic drugs 
One can use DMARDs in combination in several ways. Either the combination is used 
from the start of the drug treatment, or it is employed when single therapy does not 
suppress disease activity adequately. 
In general, two new DMARDs are given together, either at the beginning of the 
therapy or when other drugs have failed and are continued together: the "parallel"-
strategy. 
The strategy proposed by Healey and Wilske [15] comprises of the use of multiple 
second-line antirheumatic drugs used simultaneuosly at the beginning of the disease 
and, when disease control was obtained, reduce the number of drugs to a minimum 
needed to maintain disease suppression with minimal toxicity. They called it the "step-
down bridge" approach. 
A modification of this "step-down-bridge" strategy was brought forward by Wilke 
and Clough [l 1]. They suggested to divide patients in categories of disease severity as 
determined by a disease activity index and some prognostic factors. Combination 
therapy should then be reserved for patients with a moderate to severe disease, 
increasing disease severity leading to increasing number of DMARDs. 
The evaluation of these multiple drug combinations is problematic. To distinguish 
between the effects of a single or some drugs in the combination and the additional 
effects of the combined action of all drugs will need many control groups depending on 
the combinations possible with the drugs used. 
Schwarzer et al. [16] combined two drugs (prednisolone and hydroxychloroquine) 
with an alternating use of sulphasalazine and methotrexate with cycles of one month, in 
patients with refractory RA. This was done to avoid toxicity (especially nausea and 
hepatotoxicity) of the latter drugs. Although the authors state adverse events were not a 
major problem, the number of patients in their study was too low to draw any firm 
conclusion. 
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Step down bridge Step up 
Time 
Overlap and switch 
Time 
Parallel 
Time Time 
Figure 1. Strategies of combining antirheumatic drugs The single 
drugs are represented by a solid bar 
The addition-approach was brought forward by Farr, Kitas and Bacon [17]. They 
suggested to add a second DMARD when the first one does not result in a satisfying 
response: the "step-up" way. The advantage would be to avoid the greater toxicity 
encountered when drugs are given simultaneously. A negative aspect could be that it 
can take longer to achieve control of the disease. 
Another way of combining could be characterized as the "overlap & switch"-
strategy. When switching from one DMARD to another, the first one is continued 
during a limited period together with the next one and then stopped. The rationale is 
that the second agent is allowed to unfold its action, while the possible residual effect 
of the first drug is still retained. In Figure 1 the different approaches are graphically 
summarized. 
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Literature on combination therapy, general comments 
Various articles and editorials give a review of and comment on the use of 
combinations of DMARDs [18][19][20][21][22]. Recently the results of various 
randomized trials concerning the combination of DMARDs became available. The 
comparison of sulphasalazine alone, hydroxychloroquine alone and both drugs together 
showed that the combination offered no clinical benefit [13]. Combining azathioprine 
with methotrexate did not offer any clinical or radiological benefit over methotrexate 
alone [23]. Chloroquine and methotrexate were somewhat more effective than 
methotrexate alone with regards to joint count, grip-strength and functional ability, but 
not regarding other outcome variables. Notably, the combination had a slightly higher 
incidence of liver enzyme elevations [17]. Cyclosporine seemed to be of value when 
added to methotrexate when the efficacy of the latter was insufficient due to dose-
limiting toxicity in a case series by Felt et al. [24] This result was confirmed by a double 
blind, randomized trial by Tugwell and colleagues [25], where cyclosporine added to 
insufficiently effective methotrexate was superior to just continuing methotrexate. 
There was no control arm with cyclosporine alone, however, so definite conclusions 
can not be drawn. 
Data on combinations of DMARDs in arthritis other than rheumatoid arthritis are 
very scarce. In juvenile chronic arthritis (JCA) the combination of pulse therapy with 
methylprednisolone and cyclophosphamide together with oral methotrexate seemed to 
be effective and not very toxic in the systemic form of the disease [26], although it was 
a small and uncontrolled trial. Combinations of DMARDs were given to a series of 
children with JCA for reasons of significant disease activity, steroid sparing and/or 
extra-articular manifestations. For reduction of the incidence of infections and the 
possible immunomodulatory effects trimetoprim-sulphamefhoxazole was added in 
patients with systemic JCA [27]. In adults however, this antibiotic combination did not 
have an impact on disease activity [28]. In a series of 440 children with JCA more than 
50% were eventually treated with combinations of DMARDs, without apparent serious 
side effects, although no formal analysis of the clinical effects was done [29]. 
The combinations of sulphasalazine with methotrexate are discussed under the next 
heading. 
The general impression is that while definite conclusions regarding specific 
combinations cannot be drawn due to lack of randomized controlled studies, there are 
some clues that combination therapy is more effective but also more toxic. Which 
drugs to combine and how to use these combinations, to employ combinations from the 
start or to start with one and when a satisfactory respons is lacking add another, is 
unclear. 
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Sulphasalazine and methotrexate 
The "newer" DMARDs sulphasalazine (SSZ) and methotrexate (MTX) have been 
shown to be effective antirheumatic drugs with a favorable efficacy/toxicity profile and 
to have some advantages over the "older" DMARDs (gold, d-pemcillamine, (hydroxy) 
chloroquine), including an earlier onset of action and better survival curves. Combining 
the two might therefore theoretically result in an even better clinical performance. A 
favorable effect of this combination has already been described in a few cases [30] with 
little or no additional toxicity found in a retrospective study [31]. 
Table 1. Experience with the combination of sulphasalazine and methotrexate 
Author (first) 
Shiroky [30] 
Winn 
Chatham [32] 
Morgan [33] 
Morand [34] 
Shiroky [35] 
Nisar[31] 
Haagsma [37] 
Liang [36] 
O'Dell [39] 
Haagsma [38] 
Year 
1989 
1992 
1993 
1993 
1993 
1994 
1994 
1994 
1996 
1995 
Method 
Case senes 
Case senes 
Case report 
Case senes 
Case senes 
Retrospective 
Randomized, 
controlled, open 
Case senes 
Randomized, 
double blind 
Randomized, 
double blind 
Effect 
+ 
9 
9 
+ 
+ 
·>(+) 
+ 
+ 
+ 
— 
Toxicity 
-
9 
+ 9 
-
9 
-
-
9 
-
± 
Comments 
Longstanding RA, 4 patients 
Decrease in MTX induced 
nodulosis 
2daysSSZ+MTX vomitus, 
no other toxicity 
74% continuation after 2 years 
Extension of senes desenbed 
above, 20 patients (17 RA) 
Companson with MTX alone 
SSZ failure, MTX+SSZ vs 
MTX 
16 patients, dropouts 
4 toxicity, 1 inefficacy 
MTX+SSZ+HCQ vs 
SSZ+HCQ vs MTX 
Early RA, MTX+SSZ vs MTX 
vs SSZ Some increase in mild 
nausea 
+ additional efficacy /toxicity of combination compared to single drug therapy 
- no additional efficacy/toxicity of combination compared to single drug therapy 
In Table 1 the experience with the combination of sulphasalazine and MTX is 
briefly summarized. When judging the results of the various studies concerning the 
combination of sulphasalazine and MTX, a picture emerges of increased efficacy 
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without additional toxicity when the "step-up" strategy is employed in a trial on the 
combination of MTX and SSZ done in patients with more advanced RA [37]. In that 
trial a relative benefit was observed for the combination over MTX alone, in patients 
who had insufficient efficacy of sulphasalazine alone. The majority of those patients 
initially had a favorable response to SSZ. The reaction to MTX alone (with relatively 
low dose) was modest in that study. So differences between the results ofthat study and 
the study where this combination was used in a parallel design compared to the single 
agents in early RA [38], might be due to the strategy used. Triple therapy containing 
SSZ, MTX and hydroxychloroquine was reported to have superior effects over the 
combination of SSZ and hydroxychloroquine, and over MTX alone in a recently 
published study [39]. There was a remarkable difference between the treatment groups 
in favor of the triple therapy in that study. The results of SSZ in half the usual dose 
combined with a full dose of hydroxychloroquine were equal to MTX in a dose up to 
17.5 mg. Some questions remain concerning the number of patients with past use of 
SSZ and/or hydroxychloroquine and the lack of control arms with the combination of 
MTX with either SSZ or hydroxychloroquine. It was unclear why a suboptimal dose 
(half the usual one) of SSZ was chosen, which complicates conclusions about 
comparison with the treatment of SSZ with hydroxychloroquine in general. Surprising 
was the fact that ± 79% of the MTX patients had a response of at least 50% after 9 
months of treatment and no toxicity that caused withdrawal, and subsequently about 
60% of these patients dropped out because of treatment failure and/or toxicity, within 
12 months. This seems contrary to other experience with MTX, including the present 
studies (see Table 1), where, once a good response is achieved, this is maintained for 
longer time [40]. 
Conclusion 
When and how to employ which combinations of second-line antirheumatic drugs is 
still largely unclear. Several strategies, as outlined above, can be employed and are 
waiting to be examined. Combinations of chloroquine and d-penicillamine [23], of SSZ 
and hydroxychloroquine [17], of MTX and oral gold [15] and of MTX and azathioprine 
[26] probably confer no additional benefit. There are some indications that the 
combination of intramuscular gold and hydroxychloroquine and of SSZ and d-
penicillamine have increased efficacy but also increased toxicity [23]. Possibly, the 
addition of cyclosporine to MTX [29] offers better results without substantial rise in 
adverse events. A study [40] of RA patients with an insufficient response to therapy 
with SSZ results suggests that adding MTX to SSZ is clinically superior to replacing 
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SSZ for MTX, without an increase in toxicity. This supports the step-up c.q the overlap 
strategy in combination therapy. This increased efficacy was not confirmed in the study 
using the parallel strategy in patients with early RA who did not receive any DMARDs 
before starting the trial. Triple therapy of MTX, SSZ and hydroxychloroquine seemed 
to have clinically superior effects [39], although it was not clear whether all three drugs 
were neccesary to achieve this. 
Combining second-line antirheumatic drugs seems to offer clinical benefit in the 
treatment of RA, although it still is unclear what drugs, which patients, and what kind 
of strategy is to be used. 
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CHAPTER 3 
Combination of Methotrexate and Sulphasalazine in 
Patients with Rheumatoid Arthritis: Pharmacokinetic 
Analysis and Relationship to Clinical Response 
Cees J. Haagsma, Frans G.M. Rüssel, Tom В. Vree, 
Piet L.C.M. van Riel and Levinus B.A. van de Putte 
Abstract: The influence of sulphasalazine (SSZ) on the pharmacokinetics of low dose 
methotrexate (MTX) and the relation between pharmacokinetic variables and clinical response 
was studied in 15 patients with active rheumatoid arthritis despite > 6 months of SSZ treatment. 
SSZ was stopped for 2 weeks. Thereafter a single oral dose of 7.5 mg MTX was 
administered after a standard breakfast. Blood was sampled initially every 30 mm, thereafter 
hourly during 8 hours. Urine was sampled every hour Then 2000 mg SSZ daily + 7 5 mg MTX 
weekly was given. After 4 weeks the same procedure was repeated supplemented with 
concomitant administration of 1000 mg SSZ. Cluneal measurements included Ritchie articular 
index, number of swollen joints, ESR and the Disease Activity Score. Pharmacokinetic analysis 
was performed usmg a two-compartment model with first order absorption and lag time. 
Results are given as mean (sd). Paired t-test or signed rank test were applied in the statistical 
analysis. 
Pharmacokinetics of MTX without versus with SSZ, means ±sd were as follows: AUC0__: 
673 ±179 vs. 628 ±210 (95% Confidence Interval (CI)of the difference was -71 to 159) 
ng.h ml ', MRT: 5.2 ±1.3 vs. 5.2 ±1.1 (95% CI -0.4 to 0.4) h, tAX: 4.3 ±1.1 vs. 4.2 ±1.1 (95% 
CI -0.3 to 0.5) h, V/F: 59.3 ±29.3 vs. 65.5 ±25.3 (95% -23 8 to 11.4) L, CL/F: 12.3 ±5.0 vs. 
13.5 ±4 8 (95% CI -4.5 to 2.3) L.h '. CLR/F: 6.2 ±1.3 vs. 6.3 ±2.1 (95% CI -1.3 to 1.1) L.h ' . 
All p-values were > 0.3. 
A weak correlation existed between the change of ESR and the MRT, the t,^ and the V/F 
(Spearman correlation coefficients of 0.43, 0.50 and 0.50 respectively, 0.05 < ρ < 0.1). 
There is no significant influence of chronic SSZ administration on the pharmacokinetics of 
MTX or vice versa. Of the clinical variables, only the ESR correlated consistently with some 
pharmacokinetic variables of MTX. 
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Introduction 
Rheumatoid Arthritis (RA) is a disease which is often characterized by progressive and 
irreversible joint destruction, which occurs early in the course of the disease as is seen 
by radiographical analysis [1]. The results of current drug therapy are not at all 
satisfactory, as is shown in various "survival"-curves (i.e. analysis of the duration of 
use) of second-line antirheumatic drugs [2]. To tackle these problems proposals were 
brought forward to leave the current strategy of giving antirheumatic drugs in a 
sequential way, starting with the least toxic one [3][4]. One of these proposals is to 
combine different disease modifying antirheumatic drugs (DMARDs). 
Various review articles and editorials have addressed the issue of combining 
DMARDs [5][6]. The general impression is that while definite conclusions cannot be 
drawn due to lack of randomized controlled studies, there are some clues that 
combination therapy is more effective but also more toxic. Which drugs to combine 
and how to use these combinations, e.g. to employ the so called step-down bridge 
approach [4] or to start with one and when a satisfactory response is lacking add another 
[5], is unclear. 
The present study focuses on RA patients who are resistant to sulphasalazine (SSZ) 
therapy. Methotrexate (MTX) was chosen to be added to SSZ because it is likely to be 
superior to some other DMARDs with respect to efficacy and toxicity [7][8]. Also, it has 
a relatively quick onset of action and the side effects are generally quite manageable. In 
the sparse literature describing case histories in which this combination was used, a 
favourable effect has been described [9]. 
SSZ consists of two compounds, sulphapyridine and mesalazine, linked by an azo-
bond, which is split by intestinal bacteria. SSZ is variably absorbed, with estimates 
ranging from 10-30%, and undergoes extensive enterohepatic recycling. The 
metabolites of SSZ have complex dispositional characteristics [10]. MTX is an 
antifolate drug. There is interindividual variation in its bioavailability. It is bound to 
plasma proteins (35-50%) and undergoes mainly renal elimination (tubular secretion) 
[11]. 
There are very few data concerning the toxicity and no reliable data addressing the 
pharmacokinetic interaction of this combination. Theoretically there is the possibility of 
a pharmacokinetic interaction at the renal level between MTX, SSZ, sulphapyridine 
and other metabolites, since these are anionic drugs that could compete for the tubular 
organic anion excretory mechanism [12][13]. The interaction of sulphamethoxazole-
trimethoprim with MTX leading to increased toxicity is well known. This interaction 
could be due to interference with folate dependent metabolism, although for 
sulphonamides as sulphasalazine such an effect has only been described in vitro [14], 
not in vivo. The possibility of a pharmacokinetic explanation of this increased toxicity 
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has been explored [15][16], but not concerning other sulphonamides like SSZ and its 
metabolites, with low-dose MTX. 
Few data also exist relating pharmacokinetic parameters or blood levels to the 
clinical response of MTX or SSZ, and there are no data on this relationship in patients 
using the combination of the two drugs. When there is a pharmacokinetic interaction, 
e.g. an impeded excretion of MTX due to competition for renal tubular excretory 
pathways, it could lead to prolonged exposure to the drug, thus explaining possible 
clinical results of the combination. 
In the present study we tried to answer the primary question of whether there is a 
pharmacokinetic interaction between SSZ and MTX, and the secondary question of 
whether pharmacokinetic parameters can predict response and/or toxicity in RA 
patients treated with the combination of SSZ and MTX. 
Methods 
Patients 
As part of a larger open randomized clinical trial (40 patients) comparing MTX and the 
combination of MTX and SSZ, the first consecutive 15 patients with RA (ACR entena 
1987) randomized to the combination were included in the study. All were receiving 
SSZ before inclusion in the study for at least 6 months, but did not expenence 
sufficient efficacy of the drug. All had to have an estimated creatinine clearance 
(Cockcroft's rule) > 75 ml.min ', normal haematological and liver enzyme values. All 
patients had NSAIDs as co-medication, m a dose which was kept stnetly the same 
throughout the study, as was all other co-medication. Ethics Committee approval was 
obtained from the Commissie Expenmenteel Onderzoek op Mensen, Academic 
Hospital Nijmegen, the Netherlands. All patients gave their wntten informed consent. 
Experimental design 
After taking a serum sample for measurement of trough levels (15 hours after the last 
dose of SSZ) of SSZ, sulphapyndine and acetylated sulphapyndine, the medication was 
discontinued for two weeks. NSAIDs were continued m a stable dose throughout the 
study, and other co-medication was kept the same throughout the period of the study. 
Two weeks later the pharmacokinetic investigation was performed: patients received 3 
tablets of 2.5 mg MTX (Emtrexate®, Pharmachemie, Haarlem, The Netherlands) given 
in a single dose, after a standardized breakfast. Blood was collected every 30 minutes 
for the first two hours and hourly for a total of 8 hours thereafter. Urine was collected 
hourly. 
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Subsequently patients were given 7.5 mg of MTX weekly in a single dose on the 
same day of the week combined with SSZ tablets 500 mg (Salazopyrine EC®, 
Pharmacia, Uppsala, Sweden) two tablets b.i.d. 
After 4 weeks the same pharmacokinetic investigation was repeated; additionally a 
sample for determination of SSZ and metabolites was taken before ingestion of the 
tablets, and the patients received two tablets of 500 mg of Salazopyrine EC® together 
with the MTX in a single dose. 
The concentration of MTX in plasma was determined using the TDX-immunoassay 
[17] (lower detection limit 4.5 ng.ml"1, interday CV 1.4%, intraday CV 0.4%). In urine 
the MTX concentration was determined using HPLC analysis (lower detection limit 
0.25 μg.ml·1, interday CV 4.8%, intraday CV 1.4%) [18]. SSZ and metabolite 
concentrations were measured by HPLC (lower detection limit 1 μg.mΓI, interday CV 
1.3-3.4%, intraday CV 1.0-3.2%) [19]. 
The MTX drug levels were analyzed using both model-dependent and model-
independent methods. Curve fitting was done by using the nonlinear regression 
program NONLIN [20], in which plasma concentration data were weighted reciprocally 
(1/C) and cumulative amounts excreted weighted equally. Plasma concentration-time 
curves were analyzed according to a linear open two compartment model with first 
order absorption, using the following equation: 
C(t)= A.-e exp(-(t-t1>g)/T1)+ A 2e exp(-(t-tlag)/T2)-(A,+A2)-e exp(-(t-tlag)/Tabs) 
intercept of the i-th exponential phase on the Y-axis (ng/mL) 
time constant of the i-th exponential phase (h) 
absorption time constant (h) 
absorption lag time (h) 
The cumulative amount of drug excreted in the urine unchanged versus time was 
calculated as follows: 
A
e
(t)=A
e
--[l-eexp(-(t-t lai)/Ol 
where: 
A
e
": cumulative amount of drug excreted unchanged in urine to time 
infinity (mg) 
T
e
: excretion time constant (h) 
t, · excretion lag time (h) 
where: 
A,: 
T
abs : 
w 
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From these equations the following pharmacokinetic parameters can be derived: 
AUC 
AUMC 
MRT 
t*x 
CL/F 
V/F 
CLR/F 
= A.-^rT.J+Aj-ivx.J, 
= Α1·(τ1 2-τ.„>Α2·(τ2 : 
= AUMC/AUC 
= 1η2·τ2 
= D/AUC 
= DAUMC/(AUC)2-Dxlbs/AUC 
= (A
e
7D)CL/F 
where: 
AUC: area under the curve from 0 - °°, AUMC: area under the first moment 
curve from 0 - % MRT: mean residence time, t,/jL: elimination half life, CL: 
total body clearance, F: fraction absorbed (unknown), V: volume of 
distribution, CLR: renal clearance. 
AUC and AUMC were also calculated model-independently by application of 
the linear trapezoidal rule (from t= 0 to 8h and by extrapolation of the terminal 
phase of the plot to infinity). 
Clinical evaluation. 
Patients were evaluated 2 weeks before entry, and at weeks 0,4, 8, 12, 16, 20 and 24. 
All clinical evaluations were performed by one observer (CJH). 
The following changes comparing week 0 and week 24 were evaluated: the DAS 
(disease activity score [21]), the number of painful joints (53 joints were evaluated), the 
Ritchie Articular Index, the number of swollen joints (maximum of 48 joints) and 
general wellbeing expressed by the patient on a visual analogue scale of 0-100 mm. 
Compliance was checked by interviewing the patient. 
Laboratory evaluation consisted of ESR, haemoglobin content (mmol.l'1) and 
haematocrit, mean red cell volume (fl), WBC count with differential count, platelet 
count, alanine and aspartate aminotransferase, gamma glutamyl transferase, alkaline 
phosphatase and creatinine in serum (micromol.l"1). 
Toxicity was monitored every 4 weeks by interviewing the patient, physical 
examination and laboratory investigations. The following laboratory values were 
considered as an adverse drug reaction: a WBC count of less than 3.5-109.l"', platelets 
less than 120·109.Γ', a decrease of haemoglobin content of > 1.0 mmol.l "', an increase 
of serum creatinine of > 25 % and an increase of liver enzymes above the normal 
levels. 
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Statistical analysis. 
To compare the values of the derived pharmacokinetic parameters and blood levels 
during single drug use and during the use of the combination, paired t-tests were used 
in the case of normally distributed values and signed rank tests were employed when 
data had a skewed distribution. 95% confidence intervals were calculated using 
2.145-s.e.m. 
The goodness of fit to the plasma concentration and cumulative excretion data was 
evaluated through the deviations between observations and model-predicted values 
expressed as: R*= 1 - E(Dev)7 E(Obs)2. 
To test the association between the derived pharmacokinetic parameters during the 
use of the combination and clinical variables (the change from week 0 to week 24 
concerning the Ritchie articular index, the number of swollen joints, the ESR, the DAS 
score, and the occurrence of toxicity) Spearman rank correlation coefficients were 
tested. 
500 
Figure 1. Plasma concentralion-time curves of methotrexate without (*) 
and with sulphasalazme (o) Values are presented as mean and standard 
deviation 
Methotrexate and Sulphasalazine: Pharmacokinetic Analysis 33 
20 r 
Results 
Figure 2. Cumulative urinary excretion of methotrexate without О 
and with sulphasalazine (o). Values are presented as mean and 
standard deviation. 
Fifteen RA-patients were included in the study. The mean age was 59.5 years (sd 11.7), 
the female/male ratio was 12/3, the mean duration of the illness was 4.8 years (sd 4.1), 
the mean duration of SSZ-use was 18.7 months (sd 12.2). Figure 1 shows the mean 
plasma levels of MTX (with and without SSZ) and Figure 2 the mean cumulative 
urinary excretion of MTX. Table 1 shows the model-dependent values of the derived 
parameters of MTX pharmacokinetics. Model-independent analysis revealed virtually 
the same values (data not shown). The goodness of fit expressed as the mean 
coefficient of determination was 0.97 (sd 0.07), range 0.66 - 0.99, indicating very 
acceptable fits. The pharmacokinetics of MTX with or without MTX were very similar 
(Table 1). The steady state trough levels of SSZ and metabolites were not influenced by 
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co-administration of MTX either (Table 2). The clinical results of 24 weeks of 
treatment are shown in Table 3. Six patients experienced some form of toxicity. There 
were no consistent correlations between the derived pharmacokinetic parameters and 
the results of treatment or toxicity except for the decline in ESR which correlated with 
MRT, t/lX and volume of distribution (Spearman rank correlation coefficients 0.44, 0.51 
and 0.50, p-values 0.05, 0.05 and 0.1, respectively). 
Table 1. The pharmacokinetics of methotrexate (MTX) without and with concurrent administration of 
sulphasalazine 
MTX 
MTX + 
ssz 
Difference 
(95 % CI) 
p-value 
AUC,ng h ml ' 
673(179) 
628 (210) 
44 
(-71,159) 
04 
MRT, h 
5.2(13) 
5.2(1.1) 
00 
(-0 4,0 4) 
0.5 
t«.h 
4.3 (1 1) 
4.2(11) 
0.1 
(-0 3,0 5) 
06 
V/F.L 
59 3 (29 3) 
65 5 (25 3) 
-6 2 
(-23 8,114) 
0.3 
CL/F, L h"1 
12 3 (5 0) 
13.4(4 8) 
-1.1 
(-4-5,2 3) 
04 
CLR/F, L h ' 
62(13) 
6 3(2 1) 
-0 1 
(-1 3,1 1) 
08 
AUC=area under curve, MRT=mean residence time, tM= half life of elimination, V= volume of distribution, 
F= fraction absorbed (unknown), CL= total body clearance, CLR= renal clearance 
Values are presented as means (sd) unless otherwise stated 
Table 2. Trough-levels* of sulphasalazine (SSZ) and major metabolites during SSZ only and after 4 weeks of 
combination treatment with SSZ and methotrexate (MTX) 
SSZ only 
SSZ + MTX 
p-value 
SSZ 
Gigml') 
3.3 (2 1-8 2) 
3.3 (2 8-9.0) 
0 2 
Sulphapyndme 
(μ8 ml1) 
10.4(6 3-21.4) 
11.2(7.0-18.9) 
0.4 
ac-Sulphapyndme 
fog ml1) 
10 5(7 0-16 8) 
12.5(7.5-18.3) 
0.7 
* Medians (lst-3rd quartile). 
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Table 3. Clinical results of the 15 patients 
Vanable 
Ritchie articular index 
No painful joints 
No swollen joints 
Morning stiffness (mm) 
ESR (mm) 
VAS general health (mm) 
Disease activity score 
WeekO 
16(12-26) 
26(17-32) 
19(18-28) 
120(30-180) 
40 (30-53) 
64(36-81) 
4 9 (4 7-6 2) 
Week 24 
3 (2-7) 
4(2-10) 
9(2-14) 
5 (0-90) 
18(11-37) 
24(19-45) 
2 9(18-3 8) 
p-value* 
0 0001 
0 0001 
0 0001 
001 
0 007 
0 02 
0 001 
Results are expressed as medians (upper and lower quartiles) 
* the change between week 0 and week 24 was tested 
Discussion 
This study shows that there is no pharmacokinetic interaction between SSZ and MTX 
in doses used to treat rheumatoid arthritis. Nor was there a consistent correlation 
between pharmacokinetic parameters of MTX and measures of efficacy and toxicity. 
In the 15 RA patients studied, the mean values of the key parameters of single (low) 
dose MTX pharmacokinetics, e.g. the area under the curve (AUC), the mean residence 
time (MRT) and the total body clearance were statistically not different, without and 
with concomitant chronic administration of SSZ. Also, the trough serum levels of SSZ 
and major metabolites were comparable with or without MTX. A type II error seems 
unlikely given the relatively narrow 95% confidence intervals of the individual 
differences between the pharmacokinetic variables of the drugs administered singly and 
in combination. The disease activity of the patients variably decreased and there was 
considerable mtenndividual variation in the pharmacokinetics of the single dose MTX, 
but there was no consistent correlation between the two. A weak correlation existed 
between ESR and the pharmacokinetic parameters MRT, ί,/ιλ and V/F (0 05 < ρ < 0.1). 
We chose to study the kinetics of MTX in detail and of SSZ only by trough levels for 
the following reasons. First, given the large difference between the dose of MTX and 
SSZ, the latter is possibly more likely to influence the pharmacokinetics of the first 
than vice versa Second, because we wanted to study the steady state of SSZ, trough 
levels reflect well enough the levels of SSZ and its major metabolites to which the body 
is exposed. The improved clinical response to the combination of MTX and SSZ, 
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previously reported in a clinical trial [22], cannot therefore be explained by altered 
pharmacokinetics of MTX or SSZ and its major metabolites. 
The values of the pharmacokinetic parameters of MTX found in our study are in line 
with those found by others [23][24]. This is the first study specifically dealing with the 
possible pharmacokinetic interaction between SSZ and MTX. Although one other 
study [25] mentioned this combination in children with juvenile rheumatoid arthritis, no 
reliable data concerning the pharmacokinetic interaction between the two compounds 
are extractable from that article. 
We measured MTX levels in blood and urine for 8 hours. There was an excellent fit 
of the model to the data. The comparability of model-dependent and model 
independent results was good. We believe it is unlikely that longer sampling times 
would have led to other conclusions. 
The dose of NSAIDs and other concommittant medication was kept strictly the 
same, avoiding a possible bias in the results. Although some studies have mentioned an 
influence of NSAIDs on (renal) clearance of MTX [26][27], others found no 
pharmacokinetic interaction between the two when using low dose MTX, as was 
concluded in a recent review [28]. An influence of the concommittant administration of 
NSAIDs on the results is therefore unlikely. 
There are various abstracts describing the relationship between the pharmacokinetics 
of MTX and clinical results of the drug in rheumatoid arthritis. Fürst [29] found that 
toxicity correlated with 1 hour levels of MTX. In a study by Pons et al. [30] the 
elimination constant, but not the AUC correlated with the number of tender joints. 
However, no consistent partem of correlation between pharmacokinetics and efficacy 
or toxicity of MTX emerges. A study by Lafforgue et al. [31] failed to show any 
relationship between pharmacokinetics and efficacy. This is somewhat surprising 
because a dose-effect relationship is clinically obvious for all who work with this agent 
in rheumatoid arthritis and this was demonstrated in a study by Seideman [32]. 
Although our results have to be interpreted carefully because the pharmacokinetics of 
MTX were compared with the clinical results of the combination, in our study too no 
consistent correlation emerged. In most studies including ours, however, a small 
number of patients was investigated, and given the large interindividual variation a type 
II error (assuming no correlation when in fact there may be one) possibly conceals 
important relationships. 
In conclusion, no pharmacokinetic interaction between low-dose MTX and SSZ 
could be demonstrated in patients with rheumatoid arthritis. Although the sample size 
was relatively small for definite correlational analysis, there was no consistent 
relationship between pharmacokinetic parameters of MTX and efficacy and/or toxicity. 
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CHAPTER 4 
Effect of Methotrexate Alone or in Combination 
with Sulphasalazine on the Production 
and Circulating Concentrations of Cytokines 
and Their Antagonists 
Longitudinal Evaluation in Patients 
with Rheumatoid Arthritis 
Pilar Barrera, Cees J. Haagsma, Agnes M.Th. Boerbooms, Piet L.C.M.van Riel, 
George Borm, Levinus Β.Λ. van de Putte and Jos W.M. van der Meer 
Abstract: In a recent study from our group, the combination of methotrexate and 
sulphasalazine (MTX + SSZ) seemed superior to MTX alone in the treatment of rheumatoid 
arthritis. To assess the impact of these therapies on the cytokine cascade, the in-vitro 
production and circulating concentrations of several cytokines and endogenous cytokine 
antagonists were measured in 30 healthy controls and longitudinally in a subset of 26 patients 
enrolled in this study. 
Compared to controls, RA patients had significantly higher circulating concentrations of 
interleukin-6 (IL-6), soluble receptors for tumor necrosis factor (sTNFR), soluble receptors for 
interleukin-2 (sIL-2R) and interleukin-1 receptor antagonist (IL-IRA), and their peripheral 
blood mononuclear cells (PBMNC) showed a higher spontaneous production of interleukin-1 ß 
(IL-Iß), tumor necrosis factor α (TNFa) and IL-IRA (both secreted and cell-associated) and a 
higher stimulated production of cell-associated TNFa, IL-IRA and (to a lesser extent), IL-Iß. 
Treatment with MTX alone (n= 12) or combined with SSZ (n= 14), resulted in significant 
reductions of circulating IL-6 and sIL-2R but did not alter IL-Iß, TNFa or IL-IRA 
concentrations. Decreases in circulating levels of sTNFR and in the in-vitro production of cell-
associated IL-Iß and IL-IRA after stimulation were only observed in patients treated with 
MTX + SSZ. The concentrations of IL-IRA and sTNFR in the circulation exceeded moderately 
those of IL-Iß and TNFa but this is probably insufficient to block IL-1 and TNFa activity. 
In conclusion, therapy with MTX alone or with SSZ modulates IL-6 and sIL-2R 
concentrations in RA. Decreased production of IL-Iß and IL-IRA and circulating sTNFR 
levels were only observed during therapy with MTX + SSZ. Whether this relates to the better 
clinical effect observed with the combination therapy remains to be investigated. Circulating 
levels of IL-6, sIL-2R and sTNFR seem useful markers of disease activity in RA. 
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Introduction 
The involvement of cytokine networks in the pathogenesis of rheumatoid arthritis (RA) 
is proved beyond discussion [1-2]. Proinflammatory cytokines such as mterleukm-1 (IL-
1) and tumor necrosis factor cc (TNFcc) [3-4] are present in the rheumatoid synovial 
membrane and implicated in cell proliferation, synthesis of prostaglandins, 
metalloprotemases and interleukin-6 (IL-6) [5], proteoglycan breakdown and bone 
resorption [l]. Intra-articular injection of IL-1 [6] and TNF [7] result in joint 
inflammation and blocking IL-1 and TNF ameliorates several animal models of arthritis 
[8-9]. IL-6, the major inducer of acute-phase response [10], is also present in RA 
synovial tissue [2] and may amplify the inflammatory process by its action on B- and T-
cells [l]. However, in contrast to IL-1 and TNF, IL-6 does not enhance prostaglandins 
or collagenase production and may counteract inflammation by enhancing the synthesis 
of tissue inhibitor of metalloproteinase-1 [11] and reducing IL-1 and TNF production 
[12]. The role of these cytokines in human arthritis is supported by preliminary studies 
showing improvement during IL-1 [13], TNF [14], and IL-6 [15] blockade m RA patients. 
The activity of cytokines in biological fluids is subject to modulation by natural 
inhibitors and soluble cytokine receptors. The IL-1 receptor antagonist (IL-IRA), a 
competitive inhibitor of IL-1 which binds to the IL-1 receptors without inducing a 
biological response [16], is present m the rheumatoid synovial membrane [17]. High 
concentrations of soluble receptors for IL-2 (sIL-2R) [18-20] and TNF (sTNFR) [19,21] 
have been detected in plasma and synovial fluid of RA patients. The sIL-2R, a soluble 
form of the α chain IL-2 receptor, is a marker of lymphocyte activation in vivo [22] and 
may be useful to monitor disease activity in RA [18]. The two types of sTNFR (p55 and 
p75) are shed from the cellular membrane and bind to TNF in solution acting as 
endogenous TNF antagonists [23]. 
Methotrexate (MTX) and sulphasalazine (SSZ) are currently used anti-rheumatic 
drugs. Although their mechanism of action remains unclear, several reports suggest that 
these drugs may differ in their effects on circulating cytokines and cytokine production. 
In vitro studies with MTX have shown inhibitory effects on IL-1 [24] and IL-6 but not 
TNF bioactivity [25] while SSZ has been reported to decrease IL-1 [26-27] and TNF [27] 
production and to inhibit the binding of TNFcc to its receptor [28]. Furthermore in RA 
patients, decreases in synovial levels of IL-Iß [29], in the production of IL-1 by 
peripheral blood mononuclear cells (PBMNC) [30-31] and m circulating concentrations 
of IL-6, p55 sTNFR [19] and sIL-2R [19-20] have been reported during MTX, whereas 
treatment with SSZ has been associated with reductions in IL-la, IL-Iß and TNFcc [32], 
but not in sIL-2R [33] or IL-6 [32] concentrations, though the latter was not corroborated 
in other study [34]. 
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To date, the effect of combination therapy with MTX and SSZ on cytokines has not 
been assessed. Therefore, after a recent study in our centre showed that the combina-
tion of MTX and SSZ was superior to MTX alone in the treatment of active RA [35], 
we analysed the effects of these therapies on circulating levels and on the in-vitro 
production of several cytokines and their endogenous antagonists. 
Patients and methods 
Patients 
Twenty-six patients with active RA enrolled in a 24-week, randomised, open trial of 
MTX versus MTX in combination with SSZ [35] and 30 healthy controls (laboratory 
staff) were studied. Cytokine concentrations were assessed at baseline and after 4, 8, 
and 24 weeks. Fourteen additional patients enrolled in the original clinical study [35] 
were excluded from cytokine measurements since they were controlled in other centre. 
Active RA was defined as a disease activity score (DAS) > 3. The DAS is a validated 
score composed of the Ritchie Articular Index, number of swollen joints, erythrocyte 
sedimentation rate (ESR) and patient wellbeing on a visual analogue scale [36]. Twelve 
patients were allocated to therapy with MTX alone (7,5 mg weekly in a single dose) 
and 14 patients to the combination MTX + SSZ (2000 mg daily in two doses). If no 
clinical improvement was observed after 16 weeks, the MTX dose was increased to 15 
mg/week. Non-steroidal anti-inflammatory drugs (NSAIDs) were kept at stable dose 
and no corticosteroids were administered either at study entry or during the study. 
Circulating cytokine concentrations 
Blood samples used to assess circulating cytokines (IL-Iß, TNFa, IL-IRA) and soluble 
receptors (sIL-2R, sTNFR) were drawn in Vacutainer tubes (Becton & Dickinson, 
Rutherford, NJ), containing 48 μΐ EDTA-K3 and 250 μΐ aprotinin (10000 kallikrein 
inactivating units/ml, Bayer, Mijdrecht, the Netherlands). 
IL-6 was measured in serum from a Vacutainer tube without additives. Samples 
were centrifuged 10 min at 2250 g and 5 min at 15000 g to remove the platelets and 
frozen at -80° С until assay. 
Cytokine production by PBMNC 
The production of IL-Iß, TNFa and IL-IRA was assessed. sTNFR production was not 
measured since PBMNC do not seem to release these receptors either spontaneously or 
after LPS stimulation [31]. PBMNC were isolated from hepari-nized blood by Percoli 
(Pharmacia, Upsala Sweden) centrifugation (δ= 1.075 g/ml) at 4°C and washed twice in 
saline. PBMNC were suspended at a concentration of 5 * 106 cells/ml in RPMI complete 
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medium (RPMI 1640 medium with 20 mM HEPES (Flow, UK) supplemented with 2 
mM L-glutamine (Gibco, New York), 1 mM pyruvic acid (Sigma, St Louis, MO), 50 
μg/ml gentamicin and 5% heat-inactivated pooled human serum). Aliquote of 100 μΐ 
(5* 105 cells) were added to 96-well round-bottomed microtiter plates (Greiner, 
Feirickenhausen, Germany). An equal volume of RPMI complete medium with or 
without LPS (50 ng/ml final concentration) was added. The plates were incubated at 
37°C in a humidified, 5% CO
z
 atmosphere for 24 h. Thereafter, the supernatants 
containing secreted cytokines, were centrifuged for 5 min at 13000 g. The remaining 
cell fractions were resuspended in 200 μΐ RPMI complete medium/well and exposed to 
3 freeze-thaw cycles to lyse the cells and obtain material to measure cell-associated 
cytokines. The samples were stored at -80° С The RPMI culture medium, Percoli and 
saline used in this study were sterile and pyrogen-free. 
Cytokine assays 
IL-lß, TNFa [31] and IL-1RA [37] were assessed by radioimmunoassays (RIA) with 
an average sensitivity of 40, 60 and 150 pg/ml respectively. The RIAs for IL-lß and IL-
1RA are specific, i.e. the coexistence of IL-lß and IL-IRA in a given sample does not 
alter the results (unpublished results and [37]). 
IL-6 was measured by a B9 hybridoma bioassay with a sensitivity of 0.3 U/ml. As 
previously reported, this assay is not influenced by treatment with MTX or SSZ [38]. 
sTNFR (p55 and p75) were measured by enzyme-linked binding assay (ELIBA) (gift of 
Dr H. Gallati, Hoffmann la Roche, Basel, Switzerland) with a sensitivity of 100 pg/ml. 
The assays for TNFa and sTNFR measure total concentrations (both free levels and 
complexes of TNF and sTNFR) as previously reported [31]. sIL-2R was measured using 
an enzyme linked immunosorbent assay (ELISA) (Innotest hIL-2Rs, Innogenetics, В 
2000 Antwerp, Belgium), according to the manufacturer's instructions. The average 
sensitivity of this ELISA is 390 pg/ml. To minimize interassay variations, all samples 
were measured in a single assay. 
Statistical analysis 
Baseline variables were compared using the Student /-test or Wilcoxon rank sum test. 
Closed testing procedures [39] were used to compare cytokine measurements during the 
study with pretreatment values. Differences in cytokine concentrations between groups 
during the 24 week follow-up were analyzed by a distribution-free test for curve 
analysis [40]. Spearman's rank correlation coefficient was used to evaluate correlations 
between variables at study entry, and between changes in variables after 24 weeks. A 
two-sided ρ value of 0.05 was considered to be significant. The clinical trial was an 
open study [35], but cytokine measurements were performed in a modified single-blind 
fashion. 
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Results 
Clinical results 
No significant differences in pretreatment characteristics were observed between both 
treatment groups except for the number of painful joints which was higher in the group 
treated with combination therapy (Table 1). 
After 24 weeks of treatment, improvement was observed in both treatment groups. 
However, the combination therapy proved to be superior to MTX alone as reflected by 
the more pronounced changes in clinical variables including the Ritchie Articular 
Index, DAS, number of swollen and painful joints, general wellbeing, pain score, grip 
strength (Table 1) and the number of patients where the MTX dose was increased after 
16 weeks because of lack of improvement (n= 8, all but one in the MTX group). 
Toxicities occurred with similar frequency in both treatment groups and were 
observed in seven patients treated with MTX alone (gastrointestinal n= 5, increase in 
transaminases n= 2, headache n= 1, stomatitis n= 1) and in six patients treated with 
MTX + SSZ (gastrointestinal n= 2, increase in transaminases n= 5). One patient in the 
combination group dropped out at week 4 because of the development of an "overlap 
syndrome" with leucopenia, lung abnormalities, skin lesions and anti-ds DNA 
antibodies. 
The results of this small open study suggest that the combination MTX + SSZ is 
clinically superior and not more toxic than MTX alone [35]. This is currently being 
evaluated in large double-blind trials comparing MTX + SSZ versus the individual 
components. 
Baseline comparisons in cytokine concentrations 
Compared to healthy controls, the circulating concentrations of IL-6, soluble TNF and 
IL-2 receptors and IL-IRA and the spontaneous production of secreted and cell-
associated IL-lß, TNFcc and IL-1RA by PBMNC were significantly higher in RA 
patients (Table 2). The production of cell-associated cytokines after in- vitro stimula-
tion was also higher in RA patients and this difference was significant for TNFcc and 
IL-IRA. In contrast, the concentrations of IL-lß and TNFcc in the circulation and the 
secreted amount of IL-lß, TNFcc and IL-IRA after PBMNC stimulation were similar in 
patients and controls (Table 2). No differences in pretreatment levels of circulating 
cytokines or cytokine production by PBMNC were observed between treatment groups 
(data not shown). 
In RA patients, circulating IL-IRA concentrations were higher (median 4-fold) than 
those of IL-lß and the ratio sTNFR to TNFa was 20-30 and 40-70 respectively for p55 
and p75. The spontaneous production of IL-IRA in-vitro exceeded that of IL-lß by 10-
20-fold in the secreted fraction and 3-6-fold in the cell-associated fraction respectively. 
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In contrast, the median concentrations of IL-IRA and IL-Iß produced after PBMNC 
stimulation were similar (Table 2). 
Table 2. Circulating cytokines and cytokine production by PBMNC m healthy controls and RA patients at 
baseline Median and (25, 75 percentile) 
Variable Controls (n = 30) 
Circulating Concentrations 
IL-Iß (pg/ml) 
TNFa (pg/ml) 
IL-6 (U/ml) 
p55 (pg/ml) 
p75 (pg/ml) 
SIL-2R (pg/ml) 
IL-IRA (pg/ml) 
Production by PBMNC 
Secreted without stimulation 
IL-Iß (pg/ml) 
TNFa (pg/ml) 
IL-IRA (pg/ml) 
65 
105 
16 
950 
3035 
1825 
220 
100 
72 5 
2880 
Cell-associated without stimulation 
IL-Iß (pg/ml) 
TNFa (pg/ml) 
IL-IRA (pg/ml) 
Secreted after stimulation 
IL-Iß (pg/ml) 
TNFa (pg/ml) 
IL-IRA (pg/ml) 
257 
ND 
1690 
10650 
2535 
7745 
Cell-associated after stimulation 
IL-Iß (pg/ml) 
TNFa (pg/ml) 
IL-IRA (ое/тП 
4985 
195 
4860 
(ND-90) 
(85-115) 
(1 2-2 2) 
(630-1100) 
(2710-3290) 
(1300-2838) 
(205-285) 
(65-165) 
(ND-150) 
(2420-4070) 
(185-510) 
ND 
(1250-2200) 
(6970-14100) 
(1930-3590) 
(5360-10600) 
(3080-6470) 
(120-230) 
(2750-6780) 
Patients (n = 26) 
77 5 
92 5 
29 4 
2110 
4785 
4625 
312 
375 
152 5 
5305 
743 
72 5 
4810 
10500 
3445 
8990 
7690 
290 
7895 
(70-85) 
(75-105) 
(115-38 9) 
(1730-2700) 
(3720-7150) 
(3150-7200) 
(230-520) 
(155-1940) 
(65-565) 
(2480-7200) 
(485-1840) 
(35-135) 
(1270-6690) 
(4080-15400) 
(1570-5500) 
(5760-13200) 
(3520-13200) 
(185-390) 
(3430-14000) 
Ρ 
NS 
NS 
<0 001 
< 0 001 
< 0 001 
< 0 001 
0 005 
< 0 001 
001 
0 02 
< 0 001 
< 0 001 
0 005 
NS 
NS 
NS 
NS 
0 02 
0 02 
PBMNO peripheral blood mononuclear cells, ND= not detectable, NS= not significant 
Effects of treatment in cytokine concentrations 
Significant decreases in IL-6 and sIL-2R (Figure 1A and B) occurred m both treatment 
groups. The baseline concentrations of sTNFR in the circulation (Figure 1С and D) and 
the production of cell-associated IL-Iß and IL-IRA (Figure 2A and B) after PBMNC 
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stimulation tended to be higher (not significant) in patients treated with MTX + SSZ, 
and significant decreases during follow-up were only observed in this treatment group 
The secreted amount of IL-Iß after PBMNC stimulation decreased after 4 weeks, 
specially in the group treated with MTX alone, however, the median values at week 24 
were not significantly different from baseline (Figure 2C). Neither the circulating levels 
of IL-IRA (Figure IE), IL-Iß, and TNFoe nor the spontaneous production or the 
secretion of these cytokines after PBMNC stimulation (data not shown) showed 
significant changes during the study Longitudinal comparison of circulating cytokines 
and cytokine production, corrected for pretreatment values, did not show significant 
differences between treatment groups. 
Table 3. Correlation between circulating concentrations ofsTNFR and sIL-2R and several cytokines and 
clinical and laboratory parameters Spearman correlation coefficient between absolute values at entry and 
between changes versus baseline after 24 weeks 
DAS 
Swollen joints 
CRP 
Haemoglobin 
p75 
SIL-2R 
IL-6 
IL-IRA 
Entry 
0 61** 
0 67*** 
0 45* 
-0 46* 
0 81*** 
0 65*** 
0 53** 
0 61** 
P55 
24 weeks 
0 66*** 
0 64** 
0 59** 
-0 44* 
0 68*** 
0 63** 
0 52* 
0 63** 
Entry 
0 48* 
0 56** 
0 35 
-0 40* 
0 67*** 
SIL-2R 
24 weeks 
0 45* 
0 56** 
0 52* 
-0 47* 
0 68*** 
Entry 
061** 
0 59** 
P75 
24 weeks 
0 43* 
0 44* 
DAS= disease activity score, CRP= C-reactive protein 
*** ρ < 0 001, ** ρ < 0 005, * ρ < 0 05 
Interrelationships between cytokines and other parameters 
sTNFR and sIL-2R showed positive correlations with the DAS, number of swollen 
joints, C-reactive protein (CRP) and IL-6 and negative correlations with haemoglobin 
concentrations (Table 3). IL-6 measurements also correlated with baseline CRP (r= 
0 49, p < 0.05) and ESR (r= 0.58, ρ < 0.005). The production of IL-lß, TNFcx and IL-
1RA by PBMNC showed significant interrelationships but no correlation with 
circulating cytokine levels and clinical or laboratory measurements of disease activity 
(data not shown). 
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Figure 1. Circulating concentrations ofIL-6 (A), SÍL-2R (B), sTNFR (C,D), and IL-1RA (E) in 
patients treated with MTX alone (dotted boxes) or with MTX + SSZ (hatched boxes). Cytokine 
concentrations on the y axis, time in weeks on the χ axis. 
Horizontal line= median; Vertical line= range; Box= p75 andp25 values; t= value above the y 
axis range; * = ρ < 0.05 (closed testing) [39]. 
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Discussion 
In the present study circulating cytokines (IL-
lß, TNFa, IL-6, IL-IRA), soluble receptors 
(sIL-2R and sTNFR) and the production of IL-
lß, TNFa and IL-IRA by PBMNC were 
longitudinally assessed in patients with active 
RA enrolled in a randomized open trial of 
MTX combined with SSZ versus MTX alone 
[35]. Potential different effects of combination 
(MTX + SSZ) and single drug (MTX) therapy 
on the cytokine network could be relevant 
since: (a) MTX + SSZ seemed superior and 
not more toxic than MTX alone in the clinical 
study [35] and (b) previous reports had 
suggested that MTX and SSZ may differ in 
their modulation of circulating cytokines and 
cytokine production [24-33]. 
Several of the parameters studied showed 
important changes during therapy and there 
were some differences between both therapy 
groups. 
Significant decreases in the circulating 
sTNFR levels and in the production of cell-
associated IL-Iß and IL-IRA after stimulation 
were only observed in patients treated with 
MTX + SSZ but not in the MTX group 
(Figures 1 and 2). This difference may reflect 
the fact that baseline levels of these parameters 
were higher (not significant) in the group 
treated with MTX + SSZ, and that decreases 
are more likely to occur in this case. On the 
other hand, it might result from an additional 
or specific effect of SSZ on the release of TNF 
receptors and on the production of IL-1 and its 
antagonist. 
Early decreases in IL-6 and sIL-2R 
concentrations occurred in both therapy 
groups, being also more marked in the group 
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Figure 2. In vitro production of cell-associated 
1L-Iß (A), cell-associated IL-1RA (B), and 
secreted IL-ip (C) after stimulation of PBMNC 
in patients treated with MTX alone (dotted 
boxes) or with MTX + SSZ (hatched boxes). 
Cytokine concentrations on the y axis, time in 
weeks on the χ axis. 
Horizontal line= median; Vertical ¡ine= 
range; Box= p75 and p25 values; t= value 
above the y axis range; * = ρ < 0.05 (closed 
testing) [39]. 
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with higher pretreatment levels whereas the levels of IL-Iß, TNFa and IL-IRA in the 
circulation remained unchanged. 
We have previously demonstrated that MTX therapy does not alter TNFa but 
reduces IL-6 and sIL-2R concentrations [19] and this has been corroborated by other 
authors [20,41]. However, our findings in patients receiving combination therapy do not 
support that SSZ reduces circulating levels of IL-Iß and TNFa as reported by Danis et 
al. [32] 
In patients with active RA, we have observed reductions in the secretion of IL-Iß by 
stimulated PBMNC after the first MTX dose [31]. Similar effects were observed in the 
present study after 4 weeks of MTX therapy. This effect was not progressive over the 
time, and also not observed in the group treated with combination therapy which had 
lower IL-Iß secretion at baseline. Therefore, though MTX may decrease IL-Iß 
secretion in some patients in the short term, it is unlikely that this explains the sustained 
therapeutic effect of this drug. 
Our results show that, compared to healthy controls, RA patients have significantly 
higher: (a) circulating levels of IL-6, sIL2R, sTNFR and IL-1RA, (b) spontaneous 
production of secreted and cell-associated IL-Iß, TNFa and IL-IRA, and (c) stimulated 
production of cell-associated TNFa, IL-IRA and IL-Iß (not significant) by PBMNC 
(Table 2). 
Elevated concentrations of IL-6 [42-43], sIL-2R [18-20] and sTNFR [19,21] have been 
previously reported in RA. These parameters are interrelated and show positive 
correlations with some measures of disease activity (Table 3). Therefore, a decrease in 
their circulating levels during therapy probably reflects clinical improvement. Although 
it is not likely that these parameters will supersede current disease activity assessments, 
they may have some value as disease activity markers. 
In contrast, the concentrations of IL-lß [44,45] and TNFa in plasma are low and 
similar in RA patients and healthy controls. The increased serum TNFa concentrations 
reported in some studies [19,42,46] might have been due to production of TNFa in the 
blood sample during clotting or to endotoxin contamination [47,48]. Our results 
corroborate former findings of an increased spontaneous production [49-52] and a 
normal IL-lß secretion after LPS stimulation [49] in RA. 
With regard to the production of TNFa in RA, previous reports have yielded 
contradictory results [51,53]. The higher spontaneous in-vitro production of cytokines in 
RA may well reflect an activation of PBMNC in-vivo. 
When the ratio of endogenous antagonists (IL-IRA and sTNFR) to agonists (IL-1 
and TNF, respectively) was analysed, a moderate excess of the antagonists was 
observed in the circulation. The spontaneous production of IL-IRA by PBMNC was 
also somewhat higher than the IL-lß production but this was not the case after LPS 
stimulation. Furthermore, we have previously shown that PBMNC from RA patients do 
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not release sTNFR either spontaneously or after stimulation [31]. Since 10-500- and 30-
300-fold higher levels of IL-1RA [16,17] and sTNFR [54] respectively are required for 
50% suppression of IL-1 and TNF bioactivity, the concentrations of antagonists 
measured in this study may not be adequate to block completely the effects of IL-1 and 
TNF. An imbalance between IL-1 and IL-IRA has already been suggested to play a 
role in the pathogenesis of RA [17,55] and Lyme arthritis [56] and this might also be the 
case for TNFoc and its soluble receptors. This hypothesis, sustained by the promising 
results of clinical studies with IL-IRA [13] and anti-TNFoc monoclonal antibodies [14] 
in RA, encourages further research in the field of anticytokine strategies. 
Taken together, our results show that circulating concentrations of IL-6, sIL-2R, 
sTNFR and IL-IRA, the spontaneous production of IL-Iß, TNFa and IL-IRA and the 
cell-associated production of these cytokines after PBMNC stimulation are elevated in 
patients with active RA. In this open study, the combination MTX + SSZ seemed 
clinically superior to MTX alone. Reductions of circulating IL-6 and sIL-2R levels 
were observed in both treatment groups, whereas decreases in sTNFR concentrations 
and the in-vitro production of cell-associated IL-Iß and IL-IRA after stimulation 
occurred only with the combination therapy. Whether this relates to the better clinical 
effect in this patient group or is an specific effect of SSZ remains to be investigated. 
Furthermore, the circulating levels and production of endogenous antagonists for IL-1 
and TNF in RA may not be sufficient to suppress the activity of these pro-inflammatory 
cytokines. 
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CHAPTER 5 
The Influence of Sulphasalazine, Methotrexate 
and the Combination of Both on Plasma Homocysteine 
Levels in Patients with Rheumatoid Arthritis 
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Abstract: The influence of sulphasalazine (SSZ), methotrexate (MTX) and the combination 
(COMBI) of both on plasma homocysteine as an indication of interference with folate 
metabolism and the relation between plasma homocysteine and clinical effects was examined. 
105 patients with an early RA were randomized between SSZ (2-3 g/day), MTX (7.5-15 
mg/week) and the COMBI (same dose-range) and double-blindly evaluated concerning various 
measures of clinical efficacy and adverse events during 52 weeks Fasting plasma homocysteine 
and serum folate levels were determined at baseline and at 4, 8, 24 and 52 weeks Vitamin В12 
was measured at baselme The C677T mutation of the enzyme methylene-tetrahydrofolate-
reductase (MTHFR) gene was analyzed 
A slight trend towards increased efficacy and an increased occurrence of minor 
gastrointestinal toxicity was present in the COMBI group, no differences existed clinically 
between SSZ and MTX. Only a slight and temporary increase in plasma homocysteine was 
found in the SSZ group, contrary to the persistent rise m the MTX group and the even greater 
increase in the COMBI patients. Serum folate only explamed some of the variance in plasma 
homocysteine at week 52, not at other points of time Patients homozygous for the mutation m 
the MTHFR-gene had significantly higher baseline homocysteine, heterozygous MTHFR-
genotype induced a significantly higher plasma homocysteine at week 52 compared to no 
mutation No correlation was found between clinical efficacy variables and homocysteine. 
Patients with gastrointestinal toxicity had a significantly greater increase m homocysteine 
compared to patients without toxicity 
A persistent increase in plasma homocysteme levels was observed m patients treated with 
MTX alone and more pronounced in combination with SSZ Only a slight and transient rise in 
homocysteme levels was seen in the SSZ group The change in plasma homocysteme is related 
to the C677T mutation in methylenetetrahydrofolate reductase A relation of the change m 
homocysteine levels with (gastrointestinal) toxicity was found, however no relation with 
clinical efficacy existed. 
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Introduction 
The pharmacotherapy of rheumatoid arthritis consists of first line antirheumatic agents 
(non-steroidal anti-inflammatory drugs) and second-line agents, also referred to as 
disease modifying antirheumatic drugs. The latter drugs generally have a slow onset of 
action. Favorable exceptions with a relatively fast clinical impact are methotrexate 
(MTX) and sulphasalazine (SSZ) [1]. MTX is a well known anti-metabolite with 
dihydrofolate reductase inhibition as the primary target (see also Figure 1) [2]. SSZ has 
also been mentioned to have anti-folate properties, and these have been demonstrated 
partially in vitro, e.g. on dihydrofolate reductase [3]. The pharmacologically active [4] 
metabolite of SSZ, sulphapyridine, however, does not have such properties [3][5]. In 
some in vivo studies, SSZ was found to influence folate levels, possibly by interference 
with folate absorption [5]. The influence of SSZ in rheumatoid arthritis on serum folic 
acid levels has been disputed [6]. Direct influence on the folate (dependent) metabolism 
in vivo has not been investigated yet and the influence of folates on the clinical impact 
of SSZ has never been studied. In rheumatoid arthritis there is a clear folate-related 
influence of MTX on clinical efficacy and toxicity. When given folinic acid in 
relatively high doses to circumvent the blockade of dihydrofolate reductase by MTX, 
the activity of the arthritis clearly increases, demonstrating that efficacy is at least partly 
mediated by folate-dependent ways [7]. Folic acid, when given in low or higher doses 
[8] and also low-dose folinic acid [9] have a favorable influence on toxicity of MTX. 
Whether these low dosages interfere with efficacy, remains undetermined; sample sizes 
were possibly too small to proof the absence of influence on efficacy. 
The inhibition by MTX of folate metabolism can interfere with purine and 
thymidine synthesis but also with transmethylation reactions by S-adenosylmethionine, 
influencing substances involved in inflammation, e.g. adenosine and polyamines 
[10][11]. 
The combination of SSZ and MTX was found to be more effective in RA patients 
with insufficient efficacy of SSZ, than MTX alone [12]. The question raises whether 
this has to do with the influence of both drugs on folate related metabolism, analogous 
to the synergism of sulphamethoxazole and trimetoprim in treating bacterial infections. 
A way to measure the influence on folate related cellular metabolism in vivo is to 
measure plasma homocysteine [13]. A C677T polymorphism of the enzyme methylene-
tetrahydrofolate reductase (MTHFR) has shown to have influence on the reduction of 
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate which is the methylgroup 
donor of the re-methylation of homocysteine to methionine [14]. Possibly these 
alterations in plasma homocysteine could be more pronounced, when the folate 
dependent metabolism is stressed in individuals homozygous or heterozygous for this 
MTHFR-mutation by dihydrofolate reductase antagonists like MTX, or SSZ which has 
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been shown to have inhibitory effects on MTHFR in vitro [3]. Also, this mutation leads 
to redistribution of folate derivatives [15], possibly leading to altered clinical effects of 
folate-influencmg medication. 
In this randomized clinical trial comparing SSZ, MTX and the combination we 
studied whether these three medications have influence on plasma homocysteine levels, 
being an indication of interference with folate dependent metabolism, and the role of 
the C677T mutation in the MTHFR-gene in this influence. The relation of plasma 
homocysteine with clinical efficacy and toxicity of these drugs was also studied. 
N,N-dimethyl 
glycine 
R-СНз 
5'.10'
:
CH=THF 
adenosine, 
choline 
) - T H F ^ > ^ f 
""" -purine synthesis 
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cystathionine I 
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Figure 1. Folate metabolism 
DHF dihydrofolate, THF tetrahydrofoíate, 5',10-'CH2-THF methylene-THF, 5'-CH3-THF methyl-
THF, MTHFR methylenetetrahydrofolate reductase, MS methionine synthase, BHM betaine-
homocysteme methyl transferase, В12 vitamin B12 
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Patients and methods 
Hundred and five patients with active early rheumatoid arthritis, rheumatoid factor 
positive and/or HLA DR1/4 positive, were included in the study. They participated in 
an investigation examining the efficacy and toxicity of SSZ, MTX and the combination 
of both (COMBI). The design was a double blind, double dummy, controlled, 
randomized clinical trial in a setting of one academic and five non-academic 
rheumatology departments. Patients were randomized between SSZ 2000 (maximum 
3000) mg daily, or MTX 7.5 (maximum 15) mg weekly, or the COMBI. All patients 
were evaluated two-weekly the first 4 weeks and four-weekly thereafter by one 
observer for 52 weeks. Primary evaluation criterion was the mean change in the 
Disease Activity Score (DAS) over time. The DAS consists of the Ritchie articular 
index which is a weighted score of the number of painful joints, the number of swollen 
joints and the ESR [16]. Other criteria were the general wellbeing expressed by the 
patient on a visual analogue scale, the occurrence of clinically apparent adverse events 
and abnormal laboratory measurements: cytopenias, deterioration in glomerular 
filtration rate (serum creatinine > 1.5 * baseline creatinine) and liver enzyme elevations 
(alkaline phosphatase, transaminases and gamma-glutamyl transferase). Adverse events 
in general and the adverse events possibly/probably attributable to the study medication 
were analyzed by overall occurrence and occurrence by body system. 
Blood was drawn from fasting patients at a standardized time in the morning, 24 
hours after intake of the study medication. Total plasma homocysteine was measured 
by HPLC [17], serum folate and vitamin B12 were measured by radioassay [18] both at 
week 0, and folate also at weeks 4, 8, 24 and 52. The C677T mutation of the MTHFR-
gene was analyzed on DNA extracted from the patients white blood cells by PCR and 
restriction analysis [14]. 
Statistical analysis 
Continuous variables were evaluated by analysis of variance, multiple regression and t-
tests. The Tukey test was used in case of multiple comparisons. When variables were 
not normally distributed, a logarithmic or square root transformation was performed. 
The values of patients who ended the study prematurely were taken in account until 
drop-out. 
The correlation of changes in plasma homocysteine concentration and the value of 
the clinical variables (see above) at the different time-points and calculated as an area 
under the time-curve (week 0-52) was expressed by Pearson correlation coefficients. 
Comparisons of plasma homocysteine and serum folate before and during the adverse 
event of patients having an adverse event with the change of plasma homocysteine and 
serum folate of patients without an adverse event in the same period were analyzed by 
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ANOVA (if a patient had several periods without adverse events, one of these periods 
was randomly selected). The total number of adverse events as well as the number of 
adverse events per body system were analyzed for the different time-intervals. The 
differences m baseline plasma homocysteine, serum folate and vitamin В12 of patients 
with and without an adverse event were analyzed by t-tests on log-transformed values. 
Results 
One hundred and five patients participated in this study, 34 in the SSZ group, 35 in the 
MTX group and 36 in the COMBI group. There were no significant differences in 
baseline characteristics between the three treatment groups The mean age was 56.2 (sd 
12.8) years, the number of female patients 68, the number of male patients 37. The 
mean disease duration was 2.9 (sd 1.9) months. Five patients were rheumatoid factor 
negative, 100 patients had rheumatoid factor positivity. 
Table 1. Change ¡n efficacy variables, means (95% CI) 
Variable 
DAS 
No swollen joints 
Ritchie articular index 
No painful joints 
VAS general health (mm) 
ESR (mm) 
Change from baseline to week 52 
SSZ 
-18 
(-2 3,-13) 
-9 2 
(-12 2,-6 3) 
-9 2 
(-117,-6 8) 
-125 
(-15 9,-9 1) 
-15 4 
(-25 8,-5 0) 
-17 
(-26,-8) 
MTX 
-2 0 
(-2 4,-17) 
-124 
(-15 4,-9 5) 
-9 5 
(-116,-7 5) 
-15 2 
(-18 2,-12 2) 
-21 3 
(-30 2,-12 3) 
-21 
(-28,-15) 
COMBI 
-2 3 
(-2 7,-19) 
-143 
(-17 3,-114) 
-106 
(-12 5,-8 7) 
-169 
(-20 4,-13 5) 
-20 6 
(-27 6,-13 7) 
-28 
(-37,-19) 
MTX methotrexate, COMBI combination of methotrexate and sulphasalazine, SSZ sulphasalazine, DAS 
Disease Activity Score 
The baseline levels of plasma homocysteine, folate and vitamin В12 were not 
different in the three treatment groups (see Table 3). There was a significant correlation 
between baseline serum folate and baseline plasma homocysteine (Pearson's r= 0.47, ρ 
< 0.001). Z-scores of the plasma homocysteine levels before drop-out demonstrated 
that this event occurred random. 
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The clinical results are given in Table 1 and 2. There were no statistical significant 
differences in efficacy between the treatment groups (one-way ANOVA). The 
combination group tended to have a better result. However, m that group significantly 
more patients experienced nausea (Table 2). 
Table 2 Adverse events (AE), number of patients * 
Total number of patients 
Any AE 
Possible/probable* 
Withdrawal due to AE 
Nausea 
Abdominal pam/discomfort 
Stomatitis 
Pyrosis 
Increase in transaminases >2x normal 
Hematologic 
Flu/flulike symptoms/upper respiratory 
tract infection 
Dizziness 
Headache 
Neuropathy 
Dyspnea 
Rash 
SSZ 
34 
30 
16 
9 
10(1) 
9(1) 
1 
2 
4(1) 
1(1) 
6 
6 
6 
1 
2(2) 
5(3) 
MTX 
35 
27 
11 
2 
9(2) 
7 
2 
3 
5 
1 
7 
3 
4 
0 
0 
2 
COMBI 
36 
32 
23 
5 
23'(4) 
13 
2 
5 
2 
0 
10 
4 
4 
KD 
2 
0 
In brackets the number of patients withdrawing due to toxicity are given 
" one patient can contribute more than once 
' p= 0 002 (Chi-square test) 
&
 p= 0 023 (Chi-square test) 
The two treatment groups receiving MTX showed a persistent increase m 
homocysteine, contrary to the SSZ-group which did not show a persistent change; only 
in weeks 4 and 8 there was a statistically significant but slight increase in plasma 
homocysteine (Table 3 and Figure 2). This increase of plasma homocysteine by MTX 
with or without SSZ was statistically significant both compared with baseline value and 
with SSZ. MTX with or without SSZ had a statistically significant influence on the 
change in serum folate levels on all weeks (4-52). SSZ had no influence on folate 
levels. Multiple regression analysis revealed that serum folate explained some of the 
variation in plasma homocysteine at week 24 and 52 (beta -0.38 and -0.54), but also 
that MTX had a statistically significant independent influence at all weeks; this was 
more pronounced in combination with SSZ. In table 4 the relation between the 
polymorphism of the MTHFR-gene (no mutation, heterozygous, homozygous) and 
plasma homocysteine is given. Homozygous patients had significantly higher baseline 
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homocysteine concentrations compared to heterozygous individuals and patients 
without the mutation. There was an influence of the genotype on plasma homocysteine 
discernable: at week 52, patients with the heterozygous mutation had significantly 
higher plasma homocysteine levels compared to patients with no mutation. The change 
from baseline to week 52 in the heterozygous patients (see Table 4) was almost 
significantly greater than in the group of patients without the mutation (p= 0.06). The 
difference between the homozygous patients and the other groups was not significant 
anymore at week 52. There was no significant interaction between the study medication 
and the MTHFR-genotype concerning homocysteine levels at week 52 in the ANOVA. 
This excludes different effects of SSZ, MTX or COMBI on plasma homocysteine in 
the presence of different states of this enzyme. 
24 
22 
20 
1B 
16 
14 
12 
Plasma homocysteine (pmol/l) 
1
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/ . · * • • • " " 
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Figure 2. Plasma homocysteine versus lime. 
SSZ- sulphasalazine, MTX: methotrexate, COMBI: SSZ + MTX. 
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No consistent correlation between clinical efficacy variables (Ritchie articular index, 
number of swollen joints, general health as scored by the patient and ESR) and plasma 
homocysteine was found (Pearson correlation coefficients < 0.3, p-values > 0.05). 
Adverse events were analyzed both as any adverse event and possibly/probably 
attributable to the medication. A rise in plasma homocysteine (an increase of 17%, sem 
4.4%) was found in patients experiencing a gastro-intestinal adverse event (nausea, 
abdominal discomfort/pain and pyrosis taken together) without having other 
concommittant (a possibly confounding) adverse events. This rise was statistically 
significantly higher than the rise in plasma homocysteine of patients without an adverse 
event (p < 0.05). There was no statistically significant difference between patients 
having other adverse events compared to patients without any adverse event in the 
same time-interval. No relation existed between the occurrence of adverse events 
overall and plasma homocysteine concentrations. Neither was there a relationship 
between the baseline homocysteine and the occurrence of adverse events (Pearson's г 
all < 0.3). There were no relations between serum folate at any time-point and baseline 
vitamin В12 levels on one hand and occurrence of adverse events on the other. 
Table 4. Relation between methylenetetrahydrofolate reductase (MTHFR) genotype and plasma 
homocysteine, mean/median (p25, p75). 
MTHFR* 
0 
1 
2 
D-value* 
η 
40 
53 
10 
Heys" week 0 
13.6/13.9 
(11.8,15.7) 
14.6/14.6 
(12.2, 17.0) 
19.6/17.7 
(14.4,24.5) 
< 0.05.2 vs 1 and 0 
η 
31 
44 
9 
Heys* week 52* 
15.1/14.2 
(12.9,19.1) 
18.4/18.3 
(14.5,23.0) 
19.4/21.0 
(17.7,23.3) 
< 0.05. 1 vs 0 
ρ-value® 
<0.05 
<0.05 
>0.05 
0: no mutation, 1 : heterozygous, 2: homozygous for the C677T mutation. 
Homocysteine 
@
 intra-group comparison: baseline vs week 52 
inter-group comparison & 
Discussion 
In this study different effects of SSZ, MTX and the combination of the two were 
observed on plasma homocysteine levels. The two treatment groups receiving MTX 
showed a persistent increase in homocysteine, which was most pronounced in the 
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COMBI-group. No persistent influence of SSZ on plasma homocysteine existed (only 
in the early phase some significant but small effect). 
This lack of consistent effect of SSZ on plasma homocysteine in the first 
(longitudinal) study on this matter indicates that SSZ is not an efficient folate 
antagonist in vivo. Since homozygosity for C677T mutation in the MTHFR-gene, 
leading to only a slight modification of the enzyme, increases plasma homocysteine 
[14], one could speculate that SSZ is not a very efficient inhibitor of this enzyme in 
vivo. This is contrary to the results of an in vitro study [3], using suprapharmacological 
doses of SSZ which can explain the discrepancy. 
On the other hand MTX induced a clear rise in plasma homocysteine, already 
discernable in the first weeks of treatment, but clearly increasing up to 6 months of 
treatment, not significantly changing thereafter. This result differs from another study 
[19] of plasma homocysteine in MTX-treated rheumatoid arthritis patients with a 
follow-up of 24 weeks, in which no influence of MTX was found. In that study 
however most évaluable patients received folic acid; the number of patients treated 
with MTX alone was only 3. Also, blood was drawn in non-fasting state which might 
have influenced results. 
We found an additional effect of SSZ when added to MTX. The difference with 
MTX alone did not reach statistical significance, but with more patients this trend 
might have become significant. Possibly the weak and inconsistent influence of SSZ on 
folate metabolism becomes more important when this metabolism is hampered by 
MTX, resulting in an additive effect of SSZ. It is tempting to speculate that this 
possible additional influence of SSZ is somehow related to the better clinical results 
found in one study of patients with more advanced rheumatoid arthritis treated with the 
combination of SSZ and MTX [12], although the additional clinical efficacy of the 
combination was not demonstrated in the present study of early rheumatoid arthritis 
patients. 
There was some influence of the MTHFR-genotype on the impact of medication on 
the rise in plasma homocysteine: heterozygous patients had a higher plasma 
homocysteine after one year than patients without a mutation. Patients homozygous for 
the mutation started with a high plasma homocysteine and remained high, without a 
significant change. No significant differences existed between SSZ and MTX in this 
respect, although a lack of power due to a low number of patients in the various 
possible subgroups might obscure more subtle relations. Possibly, when the mutation is 
present in heterozygous form and the enzyme is further impeded either directly by SSZ 
[3] or indirectly by interference with folate metabolism by MTX, production of 
methyltetrahydrofolate will fall short with impeded methylation of homocysteine as a 
result. 
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The percentage of patients in this study with a homozygous mutation of the 
MTHFR-gene is not different from the general Dutch population [20]. 
No correlation between plasma homocysteine and clinical efficacy was found in this 
study. Two explanations exist: first, the number of patients studied was too low to 
detect subtle changes. Second, efficacy of MTX and SSZ is mediated by other 
pathways, not involving homocysteine. Although no relation was found between the 
baseline plasma homocysteine and toxicity, contrary to the study of Morgan et al. [19], 
there was a relation between the change of plasma homocysteine and the occurrence of 
side effects in this study, although this was limited to gastrointestinal toxicity. It is 
remarkable however that the patients treated with COMBI had the highest 
homocysteine levels and also had the highest occurrence of gastrointestinal side effects. 
The lack of relations with other adverse events might be due to lower number of 
patients in these categories. The absence of a relation of efficacy with plasma 
homocysteine and the presence of some relation with toxicity strengthens the notion of 
different pathways leading to efficacy and toxicity. In this respect we would like to 
postulate that the pathway involving homocysteine remethylation mediates toxicity. 
This could be further investigated by lowering homocysteine, increasing its 
remethylation by the folate independent betaine-homocysteine methyltransferase, 
giving betaine to patients experiencing toxicity. 
In this study no control group was incorporated, which might flaw the conclusions 
drawn. However it is not ethical to withhold patients with an active rheumatoid arthritis 
from proven efficacious drugs. In a pilot study of 5 patients with more advanced 
rheumatoid arthritis treated with azathioprine we found a slight but not significant 
decrease in plasma homocysteine over a period of 6 months (change -0.6 (sd 3.4) 
цтоі/і). 
Although not studied in this group of patients it seems interesting to see whether 
serum methionine would be lowered, reciprocal to the increase in plasma 
homocysteine. A pilot study of 21 patients treated with SSZ, MTX and the combination 
and the above mentioned azathioprine patients revealed no change in methionine levels 
(0.0 (sd 5.8) μπιοΙΛ). 
The impact of SSZ and MTX singly and in combination on the folate metabolism 
involving transmethylation processes needs to be further studied. The influence on 
efficacy and toxicity of SSZ and MTX mediated by the folate metabolism (by giving 
folates, and possibly betaine in pharmacological quantities), ultimately connecting it to 
inflammatory active substances (e.g. polyamines, adenosine and eventually molecules 
like cytokines) should be investigated more extensively. This could explain the 
pathways leading to efficacy and toxicity and the possible difference in these pathways 
In conclusion MTX but not SSZ leads to a consistent increase in plasma 
homocysteine levels. This increase was even more pronounced in the COMBI treated 
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patients. The change in plasma homocysteine is related to the C677T mutation in the 
methylenetetrahydrofolate reductase gene. Homocysteine did not relate with clinical 
efficacy, but a relation with gastrointestinal toxicity was observed. 
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CHAPTER 6 
Combination of Methotrexate and Sulphasalazine 
versus Methotrexate Alone 
A Randomized Open Clinical Trial in Rheumatoid Arthritis 
Patients Resistant to Sulphasalazine Therapy 
Cees J. Haagsma, Piet L.C.M. van Riel, Dirk-Jan R. A. M. de Rooij, Tom B. Vree, 
Frans G.M. Rüssel, Martin Α. van 't Hof and Levinus B.A. van de Putte 
Abstract: To compare efficacy, toxicity, and the pharmacokinetics of the combination of 
sulphasalazine (SSZ) and methotrexate (MTX) versus MTX alone in the treatment of SSZ-
resistant rheumatoid arthritis (RA) we conducted a controlled open clinical trial. 
Forty RA-patients with active arthritis despite adequate SSZ therapy, were randomly 
allocated to either SSZ + MTX or MTX alone. The patients were evaluated by a single 
observer in an open way during 24 weeks. In the first 15 patients using the combination, 
pharmacokinetics of MTX without and with SSZ were studied. 
Thirty-eight patients completed the trial. The mean decrease in the Disease Activity Score in 
the group of patients receiving the combination was significantly greater than in the MTX 
group (-2.6 versus -1.3 respectively). The same pattern was seen concerning the other efficacy 
variables. There was no difference in the occurrence of toxicity. There was no influence of SSZ 
on the pharmacokinetics of MTX. 
In conclusion in this open study the efficacy of the combination of MTX and SSZ seems to 
be superior to MTX alone, the toxicity of both therapies was similar. This effect was not 
explained by altered pharmacokinetics of MTX due to concomitant SSZ-administration. 
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Introduction 
Rheumatoid Arthritis (RA) is a disease with a course which is often characterized by 
progressive and irreversible joint destruction, already occurring early in the course of 
the disease as is seen by radiographical analysis [l]. This in turn leads to increasing 
disability. In addition several studies pointed to the increased mortality as was 
discussed by Symmons in her review article [2]. 
The results of current drug therapy are not at all satisfactory, as is shown in various 
"survival"-curves of second-line antirheumatic drugs [3]. Some patients do not respond 
at all to second line drug treatment. Even when there is initially a satisfactory respons, a 
common phenomenon is secundary resistance to treatment, leaving the treating 
physician with the dilemma what to do: replacing the ineffective drug or adding 
another? To tackle these problems proposals were brought forward to leave the 
"pyramid"-strategy [4][5][6] [7][8]. One of these proposals is to combine different disease 
modifying antirheumatic drugs (DMARDs). Also, combinations of antirheumatic drugs 
have been proposed in the initial treatment of rheumatoid arthritis [7][9], although others 
have objected to such use of combination therapy [10]. 
Arguments for combining DMARDs are the following: 
• Present single therapy is not sufficient, as explained above. 
• The pharmacodynamics of drugs can be different, the combined action might thus be 
leading to synergism or at least additive effects. 
• Lower doses of drugs with different toxicity profiles used in combination may have 
a better efficacy/toxicity ratio. 
• Using DMARDs sequentially, as is common practice, may take several drugs to find 
an effective one and thus may take a long time during which considerable damage 
can occur. Various articles and editorials give a review of and comment on the use 
of combinations of DMARDs [11][12][13][14]. The general impression is that while 
definite conclusions cannot be drawn due to lack of randomized controlled studies, 
there are some clues that combination therapy is more effective but also more toxic. 
Which drugs to combine and how to use these combinations, e.g. to employ the so 
called step-down bridge approach [4] or to start with one and when a satisfactory 
respons is lacking add another [8], is unclear. 
The present study focusses on RA patients who are resistant to sulphasalazine (SSZ) 
therapy. Methotrexate (MTX) was chosen to be added to the sulphasalazine because it 
is likely to be superior to some other DMARDs with respect to efficacy and toxicity 
[15][16]. Also it has a relative quick onset of action and the side effects are generally 
quite managable. In the (sparse) literature describing case histories in which this 
combination was used, a favourable effect has been described [17]. 
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There are very few data concerning the toxicity and no data addressing the 
pharmacokinetic interaction of this combination. Theoretically there is a possibility of a 
pharmacokinetic interaction between methotrexate and sulphapyridine and its 
metabolites, since both are anions which could compete for the renal tubular excretory 
mechanism of anions [18][19]. Although there are no studies concerning sulphasalazine 
in the doses used in RA demonstrating that efficacy or toxicity is mediated by effects of 
this drug on folic acid metabolism, in vitro data [20] and experience in gastroenterology 
[21] with this drug show some interference with folic acid action and absorption. A 
pharmacodynamic interaction on the level of folic acid metabolism could possibly lead 
to an increase in toxicity. 
In the present study we tried to answer the question whether the combination of 
methotrexate and sulphasalazine is superior to methotrexate alone in treating RA 
patients who had insufficient response to sulphasalazine alone. 
We therefore conducted a trial in patients with rheumatoid arthritis studying the 
efficacy, the toxicity and the possible pharmacokinetic interaction between 
methotrexate and sulphasalazine. 
Patients and methods 
Study design 
The study is a single-observer 24-week randomized parallel open clinical trial 
comparing efficacy and toxicity of the combination of sulphasalazine and methotrexate 
versus methotrexate alone. Forty RA-patients with insufficient effect of sulphasalazine 
were randomized using a balanced allocation method[22], in order to achieve equal 
distribution of important patient characteristics. Balancing criteria were disease 
duration, number of DMARD's used, duration of SSZ-use, gender, presence of 
rheumatoid factor, and the disease activity score. 
Single dose pharmacokinetics of MTX without SSZ and during chronic SSZ 
administration were studied in the first 15 patients using the combination. 
Patient selection 
Patients having a rheumatoid arthritis who had an insufficient response to 
sulphasalazine according to their treating physician were considered for selection. 
Entry criteria were: -1 - an age of 18 years or older, -2- RA according to the revised 
ACR criteria (1987), -3- current SSZ-treatment given for at least 6 months, but with 
insufficient effect. -4- an active arthritis defined by: a Disease Activity Score [23] (see 
below) of minimally 3.0 (corresponding with e.g. a Ritchie score of 5 plus a number of 
6 swollen joints and an ESR of 30). 
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Exclusion criteria were: -1 - preceeding treatment with methotrexate, -2- contra-
indications for the use of methotrexate: insufficient kidney-function defined as the 
estimated creatinine clearance (according to Cockcroft) less than 75 ml/min; liver 
disease i.e. clinically significant hepatic impairment: liver enzymes more than 2 times 
the upper limit of the normal values or dormant serious liver disease (e.g cirrhosis); 
uncontrolled diabetes mellitus (insulin dependent); severe congestive heartfailure; 
interstitial lung disease; active peptic ulcers; inflammatory bowel disease; 
malignancies; leukopenia: i.e. white blood cell (WBC) count < 3.5*109/1; 
thrombocytopenia: i.e. platelet count < 120*109/1; pregnancy, intended pregnancy, 
breast-feeding or inability of adequate contraception; known or suspected alcoholism. 
-3- The use of corticosteroids. -4- No informed consent. 
Treatment 
In all patients the sulphasalazine treatment was stopped for 2 weeks. Patients were then 
randomized between treatment with methotrexate (Emtrexate®, Pharmachemie, 
Haarlem, the Netherlands) alone, 7.5 mg per week given in a single dose or the 
combination of sulphasalazine enteric coated (Salazopyrine EC®, Kabi Pharmacia, 
Uppsala, Sweden) 2000 mg per day in two divided doses and a single dose of 
methotrexate 7.5 mg per week. If there was insufficient improvement after 16 weeks of 
study and the medication was tolerated, the methotrexate dose was increased to 15 mg 
per week in two divided doses with an interval of 24 hours. If unacceptable toxicity 
occurred, i.e. abnormal laboratory values as defined under the heading Toxicity, 
measured at two occasions (the liverenzymes had to be > 2 times the normal value), 
severe skin rash, pulmonary abnormalities attributable to the study drugs or intolerable 
subjective side effects, the MTX dose was reduced to 5 mg per week and the SSZ dose 
to 1000 mg or the medication was stopped, followed by a rechallenge depending on the 
severity of the adverse drug reaction. If a dose reduction had insufficient effect, folic 
acid in a dose of 1 mg daily was added [24] in case of minor toxicity. Both patients and 
the investigator were aware of the treatment assignment. 
Non-steroidal anti-inflammatory drugs were given in a stable dose. No systemic 
corticosteroids were allowed, one local injection of corticosteroids was permitted but 
discouraged; in such cases the injected joint would be excluded from analysis. 
Evaluation 
Patients were evaluated 2 weeks before entry, and on the weeks 0, 4, 8, 12, 16, 20 and 
24. 
All clinical evaluations were done by one observer (CJH). 
Primary evaluation criterium was the mean change in the Disease Activity Score 
(DAS). The DAS consists of the Ritchie Articular Index, the number of swollen joints, 
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general wellbeing as indicated by the patient on a visual analogue scale and the 
erytrocyte sedimentation rate (ESR). The DAS is a valid measure correlating well with 
other disease-variables, reflecting accurately the clinical situation and predicting the 
increase in radiological deterioration, better than the single variables do [19]. The mean 
change in DAS was calculated in the following way: the mean of the DAS scores of the 
weeks 4, 8, 12, 16, 20 and 24 minus the DAS on week 0. 
Secundary evaluation criteria were the change comparing week 0 and week 24 
concerning: the DAS score, the number of painfull joints (53 joints were evaluated and 
graded from 0 to 3), the Ritchie Articular Index, the number of swollen joints 
(Maximum of 46 joints), the duration of morning stiffness (minutes), pain expressed by 
the patient on a visual analogue scale (VAS) ranging from 0-100 mm, general 
wellbeing expressed by the patient on a VAS of 0-100 mm, grip strength (kPa) as a 
mean of two attempts using the Martin® grip strength meter [25]. 
Compliance was checked by interviewing the patient. 
Laboratory evaluation consisted of ESR, C-reactive protein (mgA), haemoglobin 
content (ттоІЛ) and haematocrit, mean red cell volume (fl), WBC count with 
differential count, platelet count, alanine and aspartate aminotransferase, gamma 
glutamyl transferase, alkaline phosphatase and creatinine in serum (тісготоІЛ). 
Toxicity was monitored every 4 weeks by 1. interviewing the patients for any new 
symptoms by a non-directive question ("did you have any adverse symptom possibly 
attributable to the medication?") and by asking a short set of questions checking 
possible adverse drug reactions of sulphasalazine and methotrexate. 2. On physical 
examination signs of possible adverse reaction (e.g. a skin rash) were sought for. 3. 
laboratory investigations. The following laboratory values were considered as an 
adverse drug reaction: a WBC count of less than 3.5*109/1, platelets less than 
120*109/1, a decrease of haemoglobin content of > 1.0 mmol/1, an increase of serum 
creatinine of > 25% and an increase of liver enzymes above the normal levels. In case 
of toxicity the medication was adjusted as described above. 
Pharmacokinetic interaction between MTX and SSZ was studied by determining the 
influence of chronic SSZ administration on the pharmacokinetics of a single dose of 
MTX as follows. After a wash-out of 2 weeks 7.5 mg of MTX (Emtrexate®) p.o., 
followed by a standardised breakfast, was given. Blood and urine were sampled, the 
first 2 hours half hourly and thereafter hourly during 8 hours. SSZ was then given 1000 
mg b.i.d. together with a weekly single dose of 7.5 mg MTX. After 4 weeks the usual 
morning dose of 1000 mg SSZ was given together with the MTX 7.5 mg followed by 
the standardised breakfast, and the same procedure was repeated. The levels of 
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methotrexate in plasma were measured using the TDX- immunoassay [26] and in urine 
by HPLC analysis. The single dose pharmacokinetic variables: Area Under the Curve 
(AUC), Mean Residence Time (MRT), Volume of distribution divided by the absorbed 
fraction (Vd/F) and the total body clearance divided by the absorbed fraction (Cl/F) 
were determined on both occasions by model-independent analysis using the nonlinear 
regression program NONLIN [27]. 
Statistical analysis. All analyses were performed using end point analysis, i.e. the last 
observation carried forwards. The primary evaluation criterium was the mean change of 
the disease activity score (see above) reflecting the area under the curve of the DAS 
corrected for the DAS at baseline. The difference of the values of this corrected area 
under the curve between the two treatment groups was tested by a Student t-test. 
Analysis of (co)variance was done to rule out confounding variables. Testing the 
changes between the week 0 and week 24 values and the mean changes of the variables 
was done using t-tests or Mann-Whitney rank sum tests, depending on the distribution 
of the data. Comparison of the two treatment groups at week 0 was done by using t-
tests, Mann-Whitney rank sum tests or chi-square testing. The difference in the 
occurrence of toxicity was studied by chi square testing. An influence of the increase of 
disease activity during wash-out and of the length of preceding sulphasalazine therapy 
in the different treatment groups was tested by analysis of variance. 
The difference in the values of the pharmacokinetic variables of single dose MTX 
pharmacokinetics without and with SSZ was tested by the Wilcoxon signed rank test 
for paired samples. 
A two-sided p-value of 0.05 was considered to be significant. 
Results 
Patients 
A total of forty patients were enrolled in the study. There were no significant 
differences in baseline characteristics between the treatment groups as shown in Table 
1. All patients were treated initially with a daily dose of 2000 mg interrupted in 2 
patients for a short time because of suspected side-effects. All but 3 patients then 
received 3000 mg daily before start of the trial with a mean length of 5.0 months (sd 
4.2). The total duration of the preceeding suphasalazine therapy was 18.9 months (sd 
12.8). There were 6 patients who received SSZ for 6 months (minimally 2 months a 
dose of 3000 mg daily), indicating a "primary" failure of the SSZ-therapy. Two 
patients, both receiving the combination treatment dropped out, one because of a 
cardiac operation and sequelae unrelated to therapy and one because of the 
Combination of Methotrexate and Sulphasalazine versus Methotrexate Alone 75 
development of an "overlap" syndrome with leucopemà, lung abnormalities, skin 
lesions and anti-ds DNA antibodies. Both dropped out at week 4 of treatment. These 
patients were included in the analyses using end-point analysis. Three patients admitted 
missing an occasional dose of trial medication (only the sulphasalazine tablets) when 
questioned about compliance, but m these occasions the percentage of medication 
taken was more than 95%. No patients received any corticosteroids systemically or 
locally during the trial. 
Table 1. Baseline characteristics of the patients, by treatment group Unless otherwise stated means (± sd) are 
given 
Variable 
No of patients 
Age (years) 
Sex (females/males) 
Disease duration (years) 
No of DM ARDS* before 
SSZ 
Duration of SSZ use 
(months) 
Rheumatoid factor positive, 
no of patients 
Ritchie articular index 
Number of swollen joints 
ESR (mm after 1 hour) 
DAS 
MTX 
18 
518(13 9) 
14/4 
53(4 2) 
1(0-4) 
20 2(13 1) 
13 
16(5 0) 
22 (7 7) 
37 (22) 
5 0 (0 7) 
COMBI 
22 
59 3(12 3) 
18/4 
4 7 (4 2) 
1(0-4) 
17 9(12 5) 
17 
19(7 9) 
23(7 5) 
44(30) 
53(11) 
p-v: 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
MTX methotrexate, COMBI combination of methotrexate and sulphasalazine, SSZ sulphasalazine, DAS 
Disease Activity Score (see text) 
* Median (range) 
Ten patients in the group receiving MTX alone had an increase in MTX dose to 15 
mg per week, in the group getting the combination (COMBI) this number was 3. 
Toxicity never prevented raising the dose in either group, only m 2 cases m the MTX 
group this increase was delayed by occurring toxicity. In two patients, both in the group 
receiving methotrexate only, the dose of methotrexate was reduced to 5 mg per week 
during 3 months both due to mouth ulcers and hair loss. In 2 patients (both receiving 
methotrexate only) the methotrexate was stopped for 2 weeks; one patient (already 
mentioned) had mouth ulcers, the other had a septic urinary tract infection. The mean 
dose of MTX m the MTX group was 8.3 mg per week, m the COMBI group this dose 
was 7.9 mg per week. 
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Response 
The difference between the two treatment groups with respect to the primary response 
criterium (the mean change of the Disease Activity Score) was 1.3: in the group getting 
MTX alone the mean change of the DAS was -1.3; in the COMBI group this change 
was -2.6. This difference was highly significant by t-testing as well as by analysis of 
(co)variance, correcting for age, sex, disease duration, presence of rheumatoid factor, 
the number of DMARDs used prior to the use of SSZ, and the duration of the 
preceding SSZ therapy. Excluding the two patients who did not complete the study, the 
results did not alter. In Figure 1 the time-course of the disease activity score is depicted. 
During the 2-week washout there is a slight but significant increase in disease activity. 
Table 2 gives the results of the change in the DAS and the secundary evaluation criteria 
i.e. components of the DAS as well as some other important variables. The number of 
patients with very good response at 24 weeks, i.e. £ 2 painful or swollen joints and an 
ESR < 15 mm after 1 hour, was 5 in the COMBI group and 0 in the MTX group. The 
mean red cell volume increased slightly but significantly in the COMBI group, the 
number of leucocytes in the combination group was significantly lower as compared to 
the methotrexate group, although all values of both groups remained in the normal 
range with the one exception as described above. 
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Figure 1. Disease Activity Score at the different visits. MTX.: methotrexate; COMBI: combination of 
methotrexate and sulphasalazine; ±: standard error of the mean. 
In both treatment groups there was no correlation between the duration of previous 
SSZ treatment and efficacy as measured by the DAS. Although there was a correlation 
between the increase in disease activity from week -2 to 0 and the mean change in the 
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DAS and the decline in the DAS at week 0 compared to week 24, these correlations did 
not differ between the two treatment groups. The explanation of these correlations is 
probably regression to the mean. Analysis of variance also failed to show an interaction 
between the difference in the disease activity score between week -2 and 0 and the 
medication used. 
Table 2. Change in clinical and laboratory variables (means ± sd). 
Variable 
DAS 
No.swollen 
joints 
Ritchie articular 
index 
No. painful 
joints 
VAS general 
health (mm) 
VAS pain (mm) 
Morning 
stiffness (min.) 
Grip strength 
right hand (kPa) 
Grip strength 
left hand (kPa) 
ESR (mm) 
Haemoglobin 
(mmol/l) 
MCV (fl) 
Leucocytes 
(*10'Л) 
Platelets (*10'/1) 
ALAT(U/1) 
Mean change 
MTX 
-1.3(0.7) 
-2.0 (4.4) 
-3.9(5.1) 
-5.1 (6.5) 
-4(15) 
-10(17) 
-15(90) 
2.3 (8.3) 
1.4(8.8) 
-6.4(14.6) 
0.03 (0.5) 
0.3 (3.6) 
-0.01 (0.9) 
-15(66) 
6.4(12.2) 
,* 
COMBI 
-2.6 (0.7) 
-10.4(4.5) 
-12.1(5.1) 
-16.1 (6.0) 
-23 (21) 
-22(21) 
-67 (62) 
10.1 (9.1) 
12.7(9.2) 
-16.0(15.5) 
0.03 (0.4) 
2.8 (4.4) 
-1.4(1.2) 
-43 (69) 
10.7(11.5) 
p-value 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
0.004 
0.04 
0.04 
0.007 
< 0.001 
0.05 
0.9 
0.02 
0.001 
0.2 
0.26 
Change, 
baseline vs end (week 24 • 
MTX 
-1.0(0.9) 
-3.7(4.7) 
-6.1(5.6) 
-7.8 (7.5) 
*v* 
-4 (23) 
-14(20) 
-21 (108) 
4.8 (8.1) 
3.9(10.8) 
-11.7(13.5) 
0.2 (0.5) 
0.3 (4.5) 
-0.5(1.4) 
-37(79) 
19.4(28.9) 
COMBI 
-2.6 (0.9) 
-13.1 (6.0) 
-14.6(6.3) 
-19.9(7.3) 
-26 (26) 
-30 (26) 
-75 (72) 
12.1 (14.5) 
17.4(13.3) 
-20.8(18.8) 
0.3 (0.5) 
4.5 (6.6) 
-1.7(1.2) 
-48 (78) 
18.0(23.8) 
 week 0) 
p-value 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
0.008 
0.03 
0.08 
0.05 
0.001 
0.08 
NS 
0.02 
0.005 
NS 
NS 
MTX: methotrexate, COMBI: combination of methotrexate and sulphasalazine, SSZ: sulphasalazine, DAS: 
Disease Activity Score (see text). 
* The mean change in the presented variables is calculated in the following way: the mean of the values of 
the concerned variable of the weeks 4, 8, 12, 16, 20 and 24 minus the value on week 0. 
Toxicity 
There were no significant differences between the treatment groups. Results are given 
in Table 3, the numbers of patients having an adverse drug reaction once or more times 
78 CHAPTER 6 
are shown. One patient in the COMBI group dropped out because of a developing 
overlap syndrome as described above. 
Pharmacokinetic interaction 
The values of the pharmacokinetic variables without and with SSZ were very similar. 
The results are given in Table 4. Thus, in these 15 patients no influence of chronic 
administration of sulphasalazme on the pharmacokinetics of MTX could be detected. 
Table 3. Adverse drug reactions (number of patients) 
Type 
Gastrointestinal 
Increase in transaminases > 2x 
normal value 
CNS (including headache and 
dizziness) 
Leucopenia 
Hairloss 
Stomatitis 
Total 
MTX 
5 
6 
2 
0 
1 
1 
11 
MTX + SSZ 
3 
6 
1 
1 
1 
0 
8 
p-value 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Table 4. Pharmacokinetic variables (model-independent) of methotrexate (MTX) without and with 
sulphasalazme (SSZ) m 15 patients (means ±sd) 
MTX without SSZ 
MTX with SSZ 
AUC(ng*h/ml) 
700 (200) 
640(210) 
MRT(h) 
6 0(14) 
6 0(15) 
V/F(l) 
73 (30) 
75 (30) 
Cl/F(l/h) 
12(5) 
13(5) 
AUC Area Under the Curve, MRT Mean Residence Time, V/F Volume of distribution/Fraction absorbed, 
Cl/F Clearance/F 
No significant differences 
Discussion 
This explorative study tackles the question concerning pharmacotherapy for RA 
whether to substitute a drug which turned out to be ineffective for another (i.e. 
sulphasalazme and methotrexate respectively) or to add the other to the first one. This 
study gives support to adding methotrexate to sulphasalazme instead of replacing 
sulphasalazme by methotrexate. A significant effect could be demonstrated when using 
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the primary outcome variable ι e. the Disease Activity Score. This difference was 
present when looking at the mean DAS corrected for week 0 as well as at the difference 
between week 0 and week 24. The individual components of the DAS, the Ritchie 
Articular Index, the number of swollen joints, the ESR and the general health score on 
a visual analogue scale changed all in favour of the combination of sulphasalazme and 
methotrexate. Also, other secundary variables (see Table 2) showed a better result for 
the combination. This favourable result was not obtained at the expense of an increased 
toxicity (see Table 3); there were no significant differences between the two treatment 
modalities with respect to adverse drug reactions. 
Notwithstanding the relatively small number of patients, this difference in the main 
outcome variable was statistically significant. Because there was only one observer, 
thus avoiding the inter-observer variation, the standard deviation was probably 
lessened. 
Of course these results have to be interpreted with caution because it was an open 
study. We chose to conduct this trial in an open way for the following reasons. This 
trial was an explorative, phase II trial, preceeding the below mentioned double blind 
trial, because very little was known about the combination of these drugs. As part of 
this phase II we wanted to study the pharmacokinetic interaction between the two 
drugs. This was only possible in patients receiving the combination. If this was done in 
a blinded fashion in fact all forty patients would have to undergo pharmacokinetic 
measurements for two days per patients, with the results only relevant in about half of 
them (the ones who would actually have received the combination). This would have 
meant a unneccesary burden to the other half of the patients and in the costs of the 
study. The second reason was the concern of toxicity; an open evaluation offered the 
best opportunity to monitor the patients more closely, not being an unusual procedure 
in phase II trials. Nonetheless the results of all variables pointed m the same direction 
making a expectation bias being responsible for the result less likely. Also, the fact that 
5 patients in the combination group and none in the group with methotrexate alone 
(two sided p= 0.08, Fisher's exact test) had a very good response (i.e. ^ 2 swollen 
and/or painful joints and an ESR < 15 mm) supports the observed difference. 
Since an increase in the dose of methotrexate was allowed only after 16 weeks of 
treatment (at the present in our institution the dose is raised after 8-12 weeks), a 
relatively low dose of methotrexate was given. In the group of patients receiving the 
combination 3 patients had an increase in MTX dose (to 15 mg/week), in the single 
treatment group the dose of MTX was raised in 10 patients. 
The relatively low mean dose of MTX might be one of the factors explaining the 
somewhat disappointing result of the therapy with methotrexate alone in this study. 
Nevertheless the decrease in disease activity score achieved by MTX alone is 
comparable to another study comparing MTX and azathiopnne [14]. In that study after 
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24 weeks a decrease in Disease Activity Score of 1.2 occurred compared to 1.0 in this 
study. The degree of reduction of disease activity in a study accomplished by MTX 
comparing it with azathioprine and the combination of both [28] was of the same 
magnitude as the effect of MTX alone in our study. 
Although all patients had an active arthitis and the treating rheumatologist wanted to 
change the second line therapy, we found evidence for a residual effect of 
sulphasalazine given the slight but significant increase in disease activity during the 
washout of sulphasalazine (see Figure 1), equal in both treatment groups. This could be 
one of the factors explaining why the combination was more effective than the single 
therapy with methotrexate. On the other hand, although there was a significant 
(negative) correlation between the increase in disease activity between week -2 and 
week 0 and the subsequent effect of the trialmedication, there was no difference 
between the treatment groups in this respect, contrary to the expectation that this 
correlation would be much stronger in the combination group. This phenomenon can 
easily be explained by a regression to the mean. 
There was no correlation between the effect of the trial medication and the 
preceding length of sulphasalazine therapy and no difference in this respect between 
the treatment groups, so that cannot explain the observed difference. 
To study the possibility of a pharmacokinetic interaction between SSZ and MTX, 15 
patients receiving the combination treatment were studied. A theoretical possibility of 
interaction between the two components is present in the mechanism of renal tubular 
excretion: both SSZ and the majority of its metabolites as well as MTX and metabolites 
are partially excreted by this mechanism. No interaction was demonstrable; the key 
pharmacokinetic variables of the single dose MTX did not differ with or without SSZ. 
Thus a concealed dose "increase" caused by adding SSZ to MTX was not present and 
therefore is not an explanation for the observed differences in effectiveness of the two 
treatments. 
The toxicity of the combination appeared to be comparable to methotrexate alone. 
There was the same pattern of toxicity, and no severe toxicity occurred which was 
definitely attributable to the medication. In one patient using the combination treatment 
a leucopenia occurred with a nadir of 2.1 *109/1, making it necessary to stop the study 
medication. After giving folinic acid the leucocyte number temporarily increased 
slightly, but later on decreased again with an active and normal haematopoiesis seen in 
the bone marrow aspirate. A picture of an overlap syndrome with interstitial lung 
disease, skin abnormalities, and an occurrence of antibodies to doublestranded DNA 
and of course arthritis developed, and resolved slowly over the following months with 
disappearance of the autoantibodies to native DNA while the patient received 
corticosteroids. Earlier in the treatment with SSZ alone she had a tendency to 
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leucopenia with occasionally values below the lower limit of normal. Possibly this 
constitutes a sulphasalazine induced autoimmune syndrome. 
The finding that there was no increase in toxicity using the combination deserves 
two remarks: firstly the number of patients treated was limited and the follow-up only 6 
months so definite conclusions cannot be drawn. Secondly one should remind that 
these were all patients who had tolerated sulphasalazine for at least 6 months so they 
were less likely to have sulphasalazine related adverse reactions. In any case no 
indication existed for a "synergism" between MTX and SSZ with respect to toxicity. 
Conclusion 
In this study of RA patients with an insufficient response to therapy with 
sulphasalazine results suggest that adding methotrexate to sulphasalazine is clinically 
superior to replacing sulphasalazine for methotrexate, without an increase in toxicity. 
This advantage of the combination is not explained by a pharmacokinetic interaction. 
Whether this result is the same for RA patients early in the course of their disease 
and in a double blind situation, is now subject to investigation at our institution in the 
RACE-trial (Rheumatoid Arthritis Combination therapy Evaluation trial), a double 
blinded, controlled trial comparing the combination of sulphasalazine and 
methotrexate versus the individual components. A similar study, in a multicentre way, 
is now performed in Finland, France and Germany. 
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CHAPTER 7 
Combination of Sulphasalazine and Methotrexate 
versus 
the Single Components in Early Rheumatoid Arthritis 
A Randomized, Controlled, Double Blind, 52 Week Clinical Trial 
Cees J. Haagsma, Piet L.C.M. van Riel, 
Alpbons J.L. de Jong and Levinus B.A. van de Putte 
On behalf of members of the STROZON research group 
This study was partly financed by Pharmacia AB, Uppsala, Sweden 
Abstract: To compare the efficacy and the safety of sulphasalazine, methotrexate, and the 
combination of both in patients with early rheumatoid arthritis (RA), not treated with disease 
modifying antirheumatic drugs previously we conducted a double blind, double dummy, 
controlled, clinical trial. 
One hundred and five patients with active, early RA, rheumatoid factor and/or HLA DR 1/4 
positive randomised between sulphasalazine (SSZ) 2000 (maximum 3000) mg daily, or 
methotrexate (MTX) 7.5 (maximum 15) mg weekly, or the combination (COMBI) of both, and 
were followed up by a single observer for 52 weeks. The mean change over time in Disease 
Activity Score (DAS) was: SSZ: -1.6 (95% CI -2.0 to -1.2); MTX: -1.7 (-2.0 to -1.4), 
COMBI: -1.9 (-2.2 to -1.6); the difference week 0-week 52 (SSZ, MTX, COMBI resp.): DAS: 
-1.8, -2.0, -2.3, Ritchie articular index: -9.2, -9.5, -10.6, Swollen joints: -9.2, -12.4, -14.3, 
ESR: -17, -21 , -28. Nausea occurred significantly more in the COMBI group. The number of 
dropouts due to toxicity were SSZ:9, MTX:2, COMBI:5. 
In conclusion there were no significant differences in efficacy between combination- and 
single therapy, only a modest trend favoring the COMBI. The results of MTX and SSZ were 
very comparable. Nausea occurred more often in the COMBI group, the number of withdrawals 
due to adverse events did not differ significantly. 
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Introduction 
The treatment of rheumatoid arthritis (RA) in its early phase relies on pharmacological 
means. Since RA is a disease which is often characterized by early occurring 
progressive and irreversible joint damage [1], and in the early phase the disease is 
probably the most responsive pharmacologically [2], drug treatment should be instituted 
early. The results of current therapy in early RA are not satisfactory due to lack of 
sufficient response. To overcome this, combinations of antirheumatic drugs were 
proposed and used, analogous to anticancer treatment [3][4][5][6]. The general 
impression is that while definite conclusions cannot be drawn due to lack of 
randomized controlled studies, there are some indications that combination therapy is 
more effective but also more toxic. Which drugs to combine and how to use these 
combinations, e.g. to start with multiple drugs and taper them off, or to start with one 
drug and, when a satisfactory response is lacking, add another, is unclear. 
The present study focusses on RA patients who had early and active disease and 
were not yet treated with DMARDs before. Participants had to have indications of a 
worse prognosis (rheumatoid factor positive and/or certain HLA types) in order to 
prevent overtreatment. Methotrexate (MTX) was chosen to be combined with 
sulphasalazine (SSZ) because both are likely to be superior to some other DMARDs 
with respect to efficacy and toxicity [7][8]. Recently we summarized the studies on this 
combination, the early impression was that the combination was effective without a 
significant rise in toxicity, in patients who had already been treated with other second-
line antirheumatic drugs [9]. 
In the present study we tried to answer the question whether the combination of 
MTX and SSZ is superior to MTX or SSZ alone, and whether there is a difference 
between MTX and SSZ in the initial treatment of early RA patients. 
Patients and methods 
Patient selection 
Patients with rheumatoid arthritis according to the ACR criteria with an age i 18 years 
and symptoms attributable to RA with a duration of 12 months maximum, were 
included. They were selected from all consecutive patients who attended 6 peripheral 
and 1 academic clinic in a period of 18 months. A positive rheumatoid factor and/or 
HLA-DR4 and/or HLA-DR1 positivity had to be present. The arthritis had to be active: 
a Disease Activity Score (DAS) being к 3.0 (see below). Preceding drag treatment for 
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RA other than analgesics and NSAIDs was not allowed. Patients with contra-
indications to the use of sulphasalazine or methotrexate were excluded. 
Informed consent had to be obtained. 
Study design 
This was a randomized, controlled, double blind 52-week trial with 1 observer. Patients 
were randomized between SSZ plus MTX-placebo, methotrexate plus SSZ-placebo and 
the combination of SSZ plus MTX. The study was approved by the ethical review 
board of each participating clinic. 
Treatment 
The patients were allocated to initial treatment with: Sulphasalazine EC 1000 mg twice 
daily in 10 days, + MTX-matching placebo, 3 tablets/week. Or: Methotrexate tablet 2.5 
mg, 3 tablets in a single dose/week, taken together + SSZ-matching placebo in the same 
dose as above. Or: Sulphasalazine + methotrexate, the same dosages as above. 
All study tablets were prepacked in blisterpackages. 
If a patient had the same or higher disease activity score (DAS, see below) and no 
prohibitive toxicity after 16 weeks of treatment with the study-medication, the 
medication was changed as follows: The SSZ (or placebo) dose was increased to 6 
tablets/day and the MTX (or placebo) dose was increased to 6 tablets/week. Once 
started, the high dose was continued throughout the study. If the higher dose was not 
effective after 8 weeks (as defined above), the patient was withdrawn. In case of 
tolerable minor toxicity the SSZ-dose (or placebo) was lowered to 2 tablets/day and the 
MTX-dose (or placebo) to 2 tablets/week. If a major severe adverse event (any event 
possibly related to the study medication causing hospitalization or death or the 
possibility to do so if the administration of the medication is continued) was suspected 
or occurred, the patient was withdrawn instantaneously. 
All patients had a concomitant NSAID in a dose which was preferably not altered 
during the study period. No corticosteroids were permitted systematically. When local 
corticosteroids had to be employed the treated joint was omitted from evaluation from 
the time of injection on. 
Evaluation 
The patients were evaluated 2-weekly the first 4 weeks and 4-weekly thereafter until 
week 52, 14 visits in total. All clinical evaluations were done by one observer (CJH). 
Primary evaluation criterion was the mean change in the Disease Activity Score 
(DAS) over time. The DAS consists of the Ritchie Articular Index, the number of 
swollen joints and the erythrocyte sedimentation rate (ESR) [10]. The mean change in 
DAS over time reflects all the changes relative to baseline and was calculated in the 
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following way: the summation of 0.5 * DAS week 2, 0.5 * DAS week 4 (only 2-weeks 
intervals) and the DASs of the next 12 visits (including week 52) divided by 13, minus 
the DAS of week 0. 
Secondary evaluation criteria were the number of patients with a good response 
according to the EULAR criteria [11], the mean change over the first 12 weeks 
(calculated in the same way as the primary efficacy variable, reflecting early changes) 
and week 0 and week 52 concerning: the DAS score, the number of painful joints (53 
joints), the Ritchie Articular Index [12], the number of swollen joints (Maximum of 44 
joints, not graded), pain expressed by the patient on a visual analogue scale (VAS) 
ranging from 0-100 mm, general wellbeing expressed by the patient on a VAS of 0-100 
mm, patient and physician global assessment of the actual disease activity (5-point 
ordinal scale) at each visit and the degree of improvement of disease activity at the final 
evaluation (on a 5 point ordinal scale), grip strength (kPa), the number of patients with 
an increase in dose, the number of joints having an intraarticular corticosteroid 
injection. 
Compliance was checked by interviewing the patient and pillcounting. 
Laboratory evaluation, performed every 4 weeks, consisted of ESR, C-reactive 
protein (mg/1), haemoglobin content (mmol/1) and hematocrit, mean red cell volume 
(fl), WBC count with differential count, platelet count, alanine and aspartate 
aminotransferase (IE/ml), gamma glutamyl transferase (IE/ml), alkaline phosphatase 
(IE/ml) and creatinine in serum (micromol/1). 
Toxicity was monitored every visit by interviewing the patients, physical 
examination and laboratory investigations. 
Statistical analysis 
All analyses were based on an intention-to-treat using end point analysis, i.e. the last 
observation carried forward. The primary evaluation criterion was the mean change of 
the DAS (see above) reflecting the area under the curve of the DAS corrected for the 
DAS at baseline. The difference of the values of this corrected area under the curve 
between the treatment groups was tested by analysis of co variance (ANCO VA). 
Analysis of covariance was done to correct for differences in baseline values. 
Comparison of the three treatment groups at week 0 and changes between the week 0 
and week 12 and week 52 values and the mean changes over time of various variables 
was done using ANCOVA, Kruskall-Wallis- or chi square tests, as appropriate. 
Survival curves were analyzed by life-table technique (log-rank test) using the 
frequencies together with the time to withdrawal. 
A two-sided p-value of 0.05 was considered to be statistically significant. 
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Results 
In the study 105 patients were included, 34 in the SSZ group, 35 in the MTX group 
and 36 in the COMBI group. The baseline characteristics of the patients are given in 
Table 1. A total of twenty patients withdrew prematurely from the trial. Three patients 
in the SSZ group and one patient in the combination group were withdrawn before the 
end of their follow-up because of inefficacy. For reasons of toxicity 9 patients in the 
SSZ group, 2 in the MTX group and 5 in the combination group ended their 
participation (see also Table 4). The median time to withdrawal was 2.2 (range 0.6, 
11.7) months in the SSZ group, 4.6 (2.6, 6.3) months for MTX and 4.1 (0.3, 8.0) 
months for the COMBI patients, the difference was significant (p= 0.006). 
Table I. Baseline characteristics, means (sd) or numbers 
Variable 
Number 
Age, years 
Female/male 
Disease duration (months) 
Rheumatoid factor positive/negative 
HLA-DR1, present/absent 
HLA-DR4, present/absent 
DAS 
No of painful/tender joints 
Ritchie articular index 
No of swollen joints 
ESR 
Nodules present/absent 
SSZ 
34 
56 8(13 0) 
21/13 
3 1 (1 9) 
33/1 
10/24 
18/16 
4 6 (0 8) 
20 8 (8 6) 
15 1(6 0) 
17 0(7 2) 
50 7(24 1) 
3/31 
MTX 
35 
54 9(13 2) 
23/12 
3 0 (2 3) 
33/2 
10/25 
18/17 
4 7 (0 9) 
20 6(8 1) 
13 4(6 4) 
19 9(8 4) 
50 3 (26 6) 
4/31 
COMBI 
36 
57 0(12 2) 
24/12 
2 6(14) 
34/2 
10/26 
18/18 
5 0 (0 8) 
24 8 (9 5) 
16 5(6 3) 
20 8 (6 9) 
55 3 (32 2) 
4/32 
The primary evaluation criterion, i.e. the mean change (95% confidence intervals) in 
DAS, by mtention-to-treat analysis was -1.6 (-2.0, -1.2) m the SSZ group, -1.7 (-2.0, 
-1.4) in the MTX group and -1.9 (-2 2, -1.6)in the COMBI group. The differences 
were statistically nor clinically significant. In Table 2 the differences between the 3 
groups are given using the adjusted means and these were tested by analysis of 
covanance to correct for the differences in baseline values. In Table 3 the results 
(unadjusted numbers) of the primary and secondary evaluation criteria are given. The 
number of patients with a response according to the ACR criteria [13] at the end of 
study were 25 for SSZ, 25 for MTX and 28 for the COMBI. According to the EULAR 
definition [11], the number patients with a good response at the end of study were 14 for 
SSZ, 15 for MTX and 14 for the COMBI. The distribution in time of good-
respondership (EULAR definition) is depicted in Figure 2. The time to good response 
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among the good-responders tended to be shorter in the SSZ group: a mean of 16.8 
weeks compared to MTX: 27.2 and COMBI: 22.4 weeks. In a life table analysis 
considering all patients this difference was not statistically significant. 
Disease Activity Score 
0 4 β 12 16 20 24 2B 32 36 40 44 48 52 
Time (weeks) 
-^SSZ • MTX -*• COMBI 
Figure 1. Mean Disease Activity Score. SSZ: sulphasalazine, MTX: 
methotrexate, COMBI: combination of both. 
The number of patients judging their disease as moderately/much improved at the 
final assessment were in the SSZ treated group: 12/11, for MTX: 12/19 and for the 
COMBI: 13/21 (p= 0.0175). These numbers were for the investigators final 
assessment: SSZ: 9/13, MTX: 15/16, COMBI: 9/22 (p= 0.06). 
Compliance. The percentage of taken tablets was > 90% in all patients in all 
subgroups. 
Dose alterations. The dose of the medication was raised in 11 patients in the SSZ 
group, in 11 in the MTX group and in 7 in the combination group (NS). 
Concomitant medication (excluding the NSAIDs): 20 patients in the SSZ group, 
15 in the MTX and 28 of the COMBI-patients had any concomitant medication. Folic 
acid was given to correct deficiency in 2 patients in the SSZ group, 1 in the MTX 
group and 3 in the COMBI group. Intraarticular injections of corticosteroids were 
sparingly and evenly administered (4 injections in SSZ, 3 in MTX, 5 in COMBI). 
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Adverse events. The number of patients experiencing some kind of adverse event 
(Table 4) was not different among the treatments. All events were reversible on 
lowering the dose or stopping the medication. The adverse events possibly or probably 
related to the treatment occurred significantly more often m the COMBI-treated 
patients. This was due to the significantly higher incidence of mild nausea. There were 
3 patients having a serious adverse event according to GCP definition, all occurring m 
the SSZ group. Two patients had dyspnea, one probably due to heartfailure and the 
other due to a chronic obstructive lung disease, although a drug induced pneumonitis 
could not be ruled out with certainty. The third patient was hospitalized for resection of 
the metatarsal heads. 
Table 4. Adverse events (AE), no of patients (reason for premature withdrawal) * 
Total number of patients 
Any AE 
Possible/probable4 
Withdrawal due to AE 
Dose reduction due to AE > 2 weeks 
Nausea 
Abdominal pain/discomfort 
Stomatitis 
Pyrosis 
Increase in transaminases >2x normal 
Hematologic 
Flu/flulike symptoms/upper respiratory 
tract infection 
CNS dizziness 
Headache 
Neuropathy 
Dyspnea 
Rash 
SSZ 
34 
30 
16 
9 
1 
10(1) 
9(1) 
1 
2 
4(1) 
1(1) 
6 
6 
6 
1 
2(2) 
5Ì3Ì 
MTX 
35 
27 
11 
2 
1 
9(2) 
7 
2 
3 
5 
1 
7 
3 
4 
0 
0 
2 
* p=0 002 
4
 p=0 023 
* one patient can contribute more than once 
Discussion 
In this double blind, randomized, double dummy controlled study of 105 early RA 
patients we tried to answer the question whether the combination of sulphasalazme and 
methotrexate is more effective than the single components, without a disproportional 
increase in toxicity and whether there was a difference between SSZ and MTX. 
COMBI 
36 
32 
23 
5 
2 
23* (4) 
13 
2 
5 
2 
0 
10 
4 
4 
KD 
2 
0 
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Although there was a slight trend that the combination was somewhat more potent than 
the individual components, the general conclusion is that the efficacy and toxicity are 
comparable in the three treatment groups. The primary efficacy variable, i.e. the mean 
change over time in the Disease Activity Score (DAS), which is a composite index 
containing the Ritchie Articular index, the number of swollen joints and the ESR, 
showed a considerable decrease from baseline to week 52 in all three groups. The 
differences between the combination therapy and the single components, although 
almost invariably in favor of the combination, were unimpressive and the relatively 
small confidence intervals [14] make important differences less likely. The difference 
between the combination and the single components in the adjusted mean change of 
DAS was 0.5 at the maximum. This difference and the maximum difference in other 
variables (see Table 2) is, to our opinion, not clinically significant and therefore the 
power of the study was sufficient. Importantly, being the first double-blind direct 
comparison between SSZ and MTX, we didn't observe any relevant differences in the 
mean change over time of the DAS between the two either in the doses used. 
Interestingly, the time to good response tended to be shorter in the sulphasalazine 
treated patients. This advantage of SSZ was lost by a tendency to loose response in the 
last part of the treatment period. The somewhat swifter reaction to SSZ was contrary to 
what we expected: one of the hypothetical advantages of combining antirheumatic 
drugs is the earlier response (less time wasted on finding an effective drug). When 
looking at Figure 2, the efficacy of the combination of SSZ and MTX is somewhere 
between SSZ and MTX in the early phase (before week 20), and tends to be superior 
thereafter. 
Given the tendency to use higher doses of MTX, one could speculate on the 
implications for the results of the present study. Possibly, a difference would arise in 
favor of MTX over SSZ. The non-significant differences between the COMBI and 
MTX now present could disappear altogether with increasing contribution of MTX to 
the efficacy of the combination. 
The toxicity was not very different, notwithstanding the statistically significant 
greater incidence of mild nausea in the combination group. This is reflected in the 
number of withdrawals, which did not differ significantly, although there was a 
tendency for a higher drop-out rate for the SSZ-treated patients, mainly due to skin 
rashes. Whether the higher number of concomitant drugs in the COMBI group could 
also explain the greater toxicity remains speculative. 
In this study we treated patients with an early rheumatoid arthritis. We chose to 
select only those with an active disease and features of a possibly bad prognosis being a 
positive rheumatoid factor (94% of the patients) and/or HLA DR1 or -DR4 positivity 
[15] [16], in order to avoid to treat patients with a good prognosis who do not need 
possibly more toxic drug-regimes. 
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% Good responders 
50 r 
0 4 β 12 16 20 24 28 32 36 40 44 48 52 
Time (weeks) 
* S S Z • MTX -^ COMBI 
Figure 2. Percentage of good responders (EULAR definition). SSZ: 
sulphasalazine, MTX: methotrexate, COMBI: combination of both. 
The place of this and other combinations of second-line antirheumatic drugs in the 
therapy of RA is still uncertain; theoretically one can adopt various strategies of 
combining [9], roughly divided into two variants: to start combinations from the 
beginning and taper them off when positive results are obtained ("Step-down-bridge" 
approach [17]) and to add a second antirheumatic drug, once the first one is not 
successful ("adding-on" or "step-up" strategy). When judging the results of the various 
studies concerning the combination of sulphasalazine and methotrexate, a picture 
emerges of increased efficacy without additional toxicity when the "step-up" strategy is 
employed [9]. The only randomized trial on the combination of MTX and SSZ was 
done in patients with more advanced RA [18]. Although it had an open design and some 
expectation bias can not be excluded with certainty, a clear benefit was observed for 
the combination over MTX alone, in patients who had insufficient efficacy of 
sulphasalazine alone. The majority of those patients initially had a favorable response 
to SSZ, preceding to the start of the trial. The reaction to MTX alone (with relatively 
low dose) was modest in that study. So differences between the results ofthat study and 
the present one might be explained by: another patient population, early vs more 
advanced RA; MTX helping to overcome secondary resistance to SSZ. The mechanism 
of this is unclear, but the folate metabolism is possibly involved [19][20]. Another 
explanation of the discrepancy between the results of the two studies might be a 
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ceiling-effect in the present study· given the large number of patients with a good 
response, there is only a limited possibility to improve further, thus compressing the 
differences. 
Another very recently published study on the combination of sulphasalazine, 
methotrexate and also hydroxychloroquine as a triple therapy in patients who failed on 
at least one DMARD, reported an increased efficacy of the triple therapy over the 
combination of sulphasalazine and hydroxychloroquine and over methotrexate alone, 
without an increase in toxicity [21]. The results of sulphasalazine in half the usual dose 
combined with a full dose of hydroxychloroquine were equal to methotrexate in a 
dose up to 17.5 mg. Controls using methotrexate with either sulphasalazine or 
hydroxychloroquine were lacking. Surprising was the fact that ± 79% of the MTX 
patients had a good response after 9 months of treatment and no toxicity that caused 
withdrawal, and subsequently about 60% of these patients dropped out because of 
treatment failure and/or toxicity, within 12 months. This seems contrary to other 
experience with methotrexate, where, once a good response is achieved, this is 
maintained for longer time [22]. 
The result of the present study, applying the "step-down-bridge" or "parallel" 
strategy in early RA, does not support the preliminary success of the combination of 
SSZ and MTX using the "step-up"-way [9]. Whether this is a result of the chosen 
strategy: the "step-up" approach is more effective than to "step-down", or depends on 
the specific antirheumatic drugs, will be clearer when other combinations of 
antirheumatic drugs will be tested in the same category of patients. 
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Summary 
The therapy of rheumatoid arthritis aiming at the underlying inflammatory proces, 
consists mainly of pharmacological means. Although knowledge of the 
pathophysiology of the rheumatoid inflammatory process is rapidly expanding, still 
little is known about the cause(s) of rheumatoid arthritis and the principal ways by 
which the disease process causes symptoms, signs and structural damage. Even the 
seemingly obvious relation between the clinical phenomena (pain and swelling) and 
structural damage to the joint can be debated. Due to this lack of insight in the basic 
mechanisms of this disease, the current pharmacotherapy of rheumatoid arthritis is 
largely based on empirical grounds. 
Generally, antirheumatic drug therapy is divided in first line therapy consisting of 
NSAIDs and second line therapy or slow acting antirheumatic drugs or disease 
modifying antirheumatic drugs, referring to their place in the sequence of treatment, 
their onset of clinical effects and their alleged capacity to alter the disease course 
respectively. Second-line therapy mostly is combined with NSAIDs or sometimes 
simple analgesics, i.e. paracetamol. An alternative classification is to divide drugs in 
symptom-modifying antirheumatic drugs and disease controlling antirheumatic therapy. 
Second line antirheumatic drugs used singly are only partly successful during a limited 
amount of time. This disappointing result has led to the employment of combinations of 
second-line antirheumatic drugs. 
Drug development is a phased proces [l], ranging from studies of healthy volunteers 
(phase I, concerning safety, biological effects and kinetics and metabolism), of 
preliminary efficacy, kinetics and metabolism in smaller patient groups (phase II), 
estimating the balance between efficacy and toxicity in larger patient samples (phase 
III), to post-marketing surveillance (phase IV). 
In Chapter 1 the classification of antirheumatic drugs as described above is discussed 
in the perspective of the kind of endpoints used: symptomatic control or patient related 
outcome, influence on the actual disease proces or on the structural damage-disease 
related outcome. In this chapter the insufficiency of single second line therapy leading 
to combination of drugs is briefly mentioned. In clinical practice the time second line 
antirheumatic drugs are used is limited due to inefficacy and toxicity; less than 50% of 
single drug courses last > 5 years. Notwithstanding attempts to choose combinations of 
drugs on the basis of assumed mechanism of action, the knowledge about the way 
drugs work is too fragmentary and too speculative to be of value in rationally choosing 
combinations. Because of their superiority in single drug therapy sulphasalazine (SSZ) 
and methotrexate (MTX) were chosen to be combined in the therapy of RA in this 
study. The pharmacokinetics, some of the possible mechanisms of action and some 
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data on efficacy and toxicity of singly used SSZ and MTX are given. Finally, the 
phases of drug development are described and the relevance of these phases for the 
design of the present studies of the combination of SSZ and MTX is explained. 
In Chapter 2 the rationale of combining second line antirheumatic drugs is given. 
Most important are the unsatisfactory results of single therapy, as described above. 
Other reasons are the possible synergism, avoidance of dose related toxicity, earlier 
finding of an effective drug and maintaining residual effects of partly insufficiently 
effective drugs used before combining. There are several strategies of combining, 
basically divided into two: starting with combination from the start of pharmacotherapy 
or adding the next drug when the first one is not (sufficiently) effective (anymore). 
The results of combinations of second line antirheumatic drugs have been mixed. 
Until recently the general impression was that there was a lack of well designed studies 
and that combinations offered at best a marginal advantage at the cost of increased 
toxicity. The last years the results of various randomized controlled trials of 
combination therapy became available. Most combinations had MTX as one of their 
components. Chloroquine plus MTX had some advantages over MTX alone, but also 
some increase in (liver) toxicity, contrary to an earlier retrospective study in which a 
lower incidence of hepatic adverse events was reported. Cyclosporine when added to 
insufficiently effective MTX was more effective than continuing MTX, but a control of 
cyclosporine alone was missing. MTX combined with SSZ and hydroxychloroquine 
was more effective than single MTX or the combination of low dose of SSZ and 
hydroxychloroquine in a single study. Remarkably, the low dose SSZ (1000 mg/day) 
combined with hydroxychloroquine was as effective as MTX in a dose up to 17.5 
mg/week in that study, although the combination of SSZ and hydroxychloroquine in 
full doses did not offer additional benefit over single therapy in another study. The 
clinical results of the combination of MTX and SSZ are discussed in Chapters 6 and 7. 
Chapter 3 deals with the possible pharmacokinetic interaction between SSZ and 
MTX in patients with RA, as a part of "phase ΙΓ'-research. The relation between 
pharmacokinetic variables and clinical response was also studied. Fifteen patients with 
RA unresponsive to SSZ were included. Trough levels of SSZ and metabolites were 
taken and after a washout of 2 weeks, single-dose pharmacokinetics of orally 
administered MTX were determined. SSZ was then started in a dose of 2 grams. After 
another 4 weeks trough levels of SSZ and metabolites and single dose 
pharmacokinetics of MTX were determined again. The patients then continued the 
combination for 5 months. There were no differences in pharmacokinetic variables of 
MTX nor in trough levels of SSZ and metabolites. The 95% confidence intervals of the 
differences of these values before and during combination indicated that there was little 
chance of meaningful differences. There was a weak correlation between the change of 
ESR and some pharmacokinetic variables of MTX (e.g. the mean residence time and 
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the half-life) but not concerning other clinical variables, although, due to the relatively 
small numbers, a type II error (assuming there is no correlation though in fact there is 
one) is possible. Other studies on this subject revealed the same absence of a consistent 
relationship between pharmacokinetic variables and clinical effects, and reported only 
incidental correlations. 
The effects of the combination of SSZ and MTX and the individual drugs on 
cytokines were the subject of study in Chapter 4. The in-vitro production and 
circulating concentrations of several cytokines and endogenous cytokine antagonists 
were measured in 30 healthy controls and longitudinally in a subset of 26 patients (12 
patients receiving MTX alone, 14 patients on the combination of MTX and SSZ) 
enrolled in the clinical study described in Chapter 6. Compared to controls, RA patients 
had significantly higher circulating concentrations of interleukin-6 (IL-6), soluble 
receptors for tumor necrosis factor (sTNFR), soluble receptors for interleukin-2 (sIL-
2R) and interleukin-1 receptor antagonist (IL-IRA), and their peripheral blood 
mononuclear cells showed a higher spontaneous production of interleukin-1 ß (IL-Iß), 
tumor necrosis factor α (TNFa) and IL-IRA (both secreted and cell-associated) and a 
higher stimulated production of cell-associated TNFa, IL-IRA and (to a lesser extent), 
IL-Iß. Treatment with MTX alone or combined with SSZ resulted in significant 
reductions of circulating IL-6 and sIL-2R but did not alter IL-Iß, TNFa or IL-IRA 
concentrations. Decreases in circulating levels of sTNFR and in the in-vitro production 
of cell-associated IL-Iß and IL-IRA after stimulation were only observed in patients 
treated with the combination. 
Biological effects of the combination were further examined in the study represented 
in Chapter 5: the influence of the combination and the single drugs on plasma 
homocysteine in patients with early RA. Plasma homocysteine is a parameter of folic 
acid metabolism, MTX is a well established folate antagonist with the primary target 
being dihydrofolate reductase and SSZ allegedly is also a folate antagonist: in vitro 
studies show impediment of various enzymes involved in folate metabolism, most 
notably on methylenetetrahydrofolate reductase (MTHFR). The impact of a mutation of 
the MTHFR-gene was studied. Only a slight and temporary increase in plasma 
homocysteine was found in the SSZ group, contrary to the consistent rise in the MTX 
treated patients, the COMBI-group showed the largest increase. Serum folate only 
explained some of the variance in plasma homocysteine at week 24 and 52, not at other 
points of time. Patients with a homozygous mutation of the MTHFR-gene had 
significantly higher baseline homocysteine, heterozygous mutation of the MTHFR-gene 
lead to significantly higher plasma homocysteine at week 52 compared to patients 
without the mutation, in all three treatment groups. No correlation was found between 
clinical efficacy variables and homocysteine. Patient with gastrointestinal toxicity had a 
significantly greater increase in homocysteine compared to patients without toxicity. 
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Chapter 6 also concerns phase II of the evaluation of the combination: the clinical 
testing of the combination in patients who did not have a sufficient response to SSZ for 
at least 6 months in an open design. After a washout of two weeks forty consecutive 
patients with rheumatoid arthritis with a mean duration of about 5 years despite SSZ in 
doses up to 3 grams per day were randomized between MTX alone (the next step in the 
therapeutic sequence in our hospital) and the combination of SSZ with MTX. The 
initial dose of MTX was 7.5 mg/week in a single dose and could be increased to 15 
mg/week in case of insufficient response. The dose of SSZ was 2000 mg/day. Both 
patients and the investigator were aware of the treatment assignment for reasons of 
monitoring; this was the first larger scale use of this combination and 15 of the patients 
using the combination were involved in the pharmacokinetic study described in 
Chapter 3. All observations were done by one investigator. The results were analyzed 
using endpoint analysis, i.e. the last observation carried forwards. The two treatment 
groups were comparable at baseline. Thirty-eight patients completed the trial. Two 
patients dropped out, both in the combination group, one due to the development of a 
lupus-like disease, possibly linked to the medication, and the other due to a cardiac 
operation, thought to be unrelated to the medication. The mean decrease in the Disease 
Activity Score in the group of patients receiving the combination was greater than in 
the MTX group (-2.6 versus -1.3 respectively), being a both clinically and statistically 
significant difference. The same pattern was seen concerning the other efficacy 
variables. There was no difference in the occurrence of toxicity; 11 patients receiving 
MTX alone and 8 patients in the combination group experienced some kind of toxicity. 
The clinical testing was expanded to patients with an early rheumatoid arthritis as 
described in Chapter 7. This was a larger, phase III study including 105 patients. All 
patients had an early rheumatoid arthritis: symptoms and/or signs of polyarthritis of less 
than 12 months duration. The objective of this study was to compare the efficacy and 
the safety of sulphasalazine, methotrexate , and the combination of both in patients 
with early RA, not treated with disease modifying antirheumatic drugs previously. It 
was a double blind, double dummy, controlled, randomized clinical trial, done in one 
academic and five non-academic rheumatology departments. The patients had to have 
an active, early RA. As indicators of an unfavorable prognosis rheumatoid factor and/or 
HLA DR 1/4 had to be present to avoid overtreatment. Patients were randomized 
between SSZ 2000 (maximum 3000) mg daily, or methotrexate (MTX) 7.5 (maximum 
15) mg weekly, or the combination (COMBI) of both. There were no statistically 
significant differences between the treatment groups in baseline values. The mean 
changes over time in Disease Activity Score (DAS) which reflects the area under the 
curve corrected for the baseline value were respectively: SSZ: -1.6 (95% Confidence 
Intervals (CI) -2.0 to -1.2); MTX: -1.7 (CI: -2.0 to -1.4), COMBI: -1.9 (CI: -2.2 to 
-1.6). Differences between baseline and end of study revealed the same pattern: a slight 
104 CHAPTER 8 
trend towards better efficacy in the COMBI treated patients, but statistically and 
clinically not significant. The number of patients withdrawn due to inefficacy were 
three in the SSZ-group, zero in the MTX-group, and one in the COMBI-group. The 
number of patients with an increase in dose were 11 in the SSZ group, 11 for MTX and 
7 for the combination of both. The incidence of any adverse event was high and equally 
distributed over all treatment groups. Nausea occurred significantly more in the 
COMBI group. The number of dropouts due to toxicity was not significantly higher 
among the SSZ treated patients mainly due to skin rashes. In conclusion there was no 
added value of the combination compared to the single drugs, only a slight trend 
towards increased efficacy for the combination. The confidence intervals precluded 
important differences however. Minor toxicity occurred somewhat more frequent in the 
combination group. 
Discussion 
The place of the combination of SSZ and MTX in the pharmacological armamentarium 
against rheumatoid arthritis was examined in the studies described in this thesis. The 
phases of drug development were used as a framework, although the formal sequence 
in time was not strictly adhered to. In a phase II study of more advanced RA not 
responding to SSZ anymore, the combination of SSZ and MTX seems to offer 
advantages over MTX alone, supporting the step-up approach of combining 
antirheumatic drugs (Chapter 6). In early RA however, the combination used in a 
parallel-strategy phase III study, did not offer substantial increase in efficacy, and was 
slightly more toxic than SSZ or MTX alone (Chapter 7). The majority of the patients 
initially described in Chapter 6 had a favorable response to SSZ, preceding to the start 
of the trial. The reaction to MTX alone (with relatively low dose) was modest in that 
study. So differences between the results of the study using the step-up approach and 
the parallel approach used ab initio might be explained by another patient population, 
early versus more advanced RA. Further explanation could be that MTX helps to 
overcome secondary resistance to SSZ: most of the patients involved in the study using 
the step-up strategy initially had a favorable reaction to SSZ, but this efficacy was lost 
during further treatment. Possibly, MTX interferes with the mechanism of inducible 
drug-resistance to SSZ. The way MTX could accomplish this is unclear, but the folate 
metabolism is possibly involved (Chapter 5). Another explanation of the discrepancy 
between the results of the two studies might be a ceiling-effect in the early RA study: 
given the large number of patients with a good response, there is only a limited 
possibility to improve further, thus compressing the differences. 
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The encountered clinical differences between the combination and MTX alone in 
Chapter 6 were not explained by an interaction on the pharmacokinetic level, which 
was not present (Chapter 3). In line with this there were no consistent relations between 
pharmacokinetic variables and clinical effects. Since pharmacokinetic differences did 
not exist, the question raises whether pharmacodynamic differences might explain the 
observed clinical differences. We therefore studied the possible influence of the two 
drugs on plasma homocysteine which reflects alterations of folate dependent cellular 
metabolism (Chapter 5) as the next step in the possible mechanism of action of the 
combination. Although no influence of SSZ alone on plasma homocysteine was found, 
this drug seemed to augment the influence of MTX on this level. Another finding was 
the influence of the C677T mutation of methylenetetrahydrofolate reductase on plasma 
homocysteine: heterozygous mutation lead to higher homocysteine levels after one year 
of treatment, no difference existed between the three treatment groups. Possibly, when 
the mutation is present in heterozygous form and the enzyme is further impeded either 
directly by SSZ or indirectly by interference with folate metabolism by MTX, 
production of methyltetrahydrofolate will fall short with impeded remethylation of 
homocysteine as a result. The relationship of plasma homocysteine with clinical 
variables was not present concerning efficacy but some relationship existed with 
(gastrointestinal) toxicity. Together with the results of trials in which a relation of 
homocysteine with toxicity was also found and the finding that folic acid and folinic 
acid only in low dose influence toxicity but probably not efficacy, indicate that folic 
acid related metabolic pathways mediating efficacy and toxicity differ. Homocysteine-
related pathways are possibly involved in toxicity only. This could further be tested by 
specifically interfering with the methylation of homocysteine to methionine, e.g. with 
supplementation of betaine. 
Starting at the other end of the chain of events representing the possible mode of 
action, the influence of the combination on inflammation was studied (Chapter 4). We 
did this by examining circulating cytokines and cytokine production by leukocytes. 
There were some clues that the combination had some additional effects as reflected by 
more pronounced influence on soluble TNF receptors and cellular production of II-Iß 
and II-1 receptor antagonist. Whether these changes really explained (some) of the 
clinical differences found, is still unproven because the evidence of a causal relation 
between these pharmacodynamic changes and clinical effects has not been provided. 
Briefly, the combination of SSZ and MTX can not be recommended to be used in a 
parallel approach from the start of the pharmacotherapeutic career of an RA patient, but 
seems to offer some advantages in a step-up strategy when SSZ has insufficient 
efficacy. 
Future studies on the combination of SSZ and MTX have to be directed at the use of 
this combination in patients who failed on both SSZ and MTX monotherapy and the 
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use of this combination in SSZ-failures who were not yet treated with MTX (and vice 
versa) has to be further confirmed clinically. The impact of SSZ and MTX singly and 
in combination on the folate metabolism involving transmethylation processes needs to 
be further examined. The influence on efficacy and toxicity of SSZ and MTX mediated 
by the folate metabolism (by giving folates, and possibly methylated moieties like 
betaine, in pharmacological quantities), ultimately connecting it to inflammatory active 
substances (e.g. polyamines, adenosine and eventually molecules like cytokines) should 
be investigated more extensively. This could explain the pathways leading to efficacy 
and toxicity and the possible difference in these pathways. 
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Samenvatting 
De therapie van reumatoide artritis (RA, chronisch gewrichtsreuma) is er op gericht het 
onderliggende ontstekingsproces te onderdrukken of de gevolgen ervan te verzachten. 
Geneesmiddelen spelen hierbij een centrale rol. Hoewel de kennis van 
ontstekingsprocessen snel toeneemt, is er nog weinig bekend over de oorza(a)k(en) van 
RA en de manieren waarop het ziekteproces symptomen en ook structurele schade 
veroorzaakt. Zelfs de ogenschijnlijk duidelijke relatie tussen de verschijnselen zoals 
pijn en zwelling van een gewricht en de beschadiging ervan kan worden betwijfeld. 
Door dit gebrek aan inzicht in de mechanismen van deze ziekte is de huidige 
geneesmiddeltherapie voornamelijk op ervaring gegrond. 
Over het algemeen wordt de antireumatische medicamenteuze therapie ingedeeld in 
een eerste lijn bestaande uit ontstekingsremmende pijnstillers en een tweede lijn 
ofwel langzaamwerkende c.q. ziektebeloop beïnvloedende geneesmiddelen. Deze 
indeling verwijst naar de veronderstelde plaats van de diverse middelen in de 
behandelingsvolgorde, hun snelheid van inwerken en hun verondersteld vermogen om 
de koers van de ziekte daadwerkelijk te wijzigen. Tweedelijns geneesmiddelen worden 
veelal gecombineerd met ontstekingsremmende pijnstillers, soms met simpele 
pijnstillers zoals paracetamol. Helaas is ook het effect van tweedelijns middelen slechts 
relatief kortdurend en vaak niet afdoende. Deze teleurstellende resultaten hebben geleid 
tot het inzetten van combinaties van tweedelijns middelen. 
Nieuwe geneesmiddelen dienen systematisch te worden onderzocht. Dit geldt 
mutatis mutandis ook voor nieuwe combinaties van reeds gebruikte geneesmiddelen. 
De ontwikkeling van nieuwe geneesmiddelen is een gefaseerd proces [1], beginnend bij 
onderzoek bij gezonde vrijwilligers (fase 1, betreffende veiligheid, biologische effecten 
en farmacokinetiek: opname, verdeling, stofwisseling en uitscheiding van stoffen), 
vervolgens eerste ervaringen met patiënten met betrekking tot effect en 
bovengenoemde zaken (fase 2) en het vaststellen van de balans tussen effectiviteit en 
veiligheid in grotere groepen patiënten (fase 3) en tenslotte geneesmiddel "bewaking" 
na het op de markt brengen van het middel (fase 4). In het hierna volgende zal een 
drietal fase 2 onderzoeken met de nadruk op farmacokinetiek en biologische effecten 
(Hoofdstuk 3, 4 en 5), een fase 2 onderzoek naar effectiviteit en veiligheid (Hoofdstuk 
6) en een fase 3 onderzoek (Hoofdstuk 7) worden gepresenteerd. 
In Hoofdstuk 1 wordt de classificatie van antireumatica en het tekortschieten van 
enkelvoudige tweedelijns therapie leidend tot combinaties beschreven. In de klinische 
praktijk blijkt de duur van het gebruik van een tweedelijns middel beperkt te zijn door 
gebrek aan effectiviteit en het optreden van bijwerkingen: minder dan 50% wordt 
langer gebruikt dan 5 jaar. Ondanks pogingen om combinaties van tweedelijns 
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antireumatica op rationele gronden te kiezen, gebaseerd op veronderstelde 
werkingsmechanismen, blijkt de kennis over deze mechanismen te fragmentarisch en te 
speculatief te zijn om een rationele keuze te leiden. Voor het in dit proefschrift 
weergegeven onderzoek zijn sulfasalazine (SSZ) en methotrexaat (MTX) geselecteerd 
ter combinatie in de behandeling van RA, gezien hun superioriteit in enkelvoudige 
therapie. De farmacokinetiek, enkele van de mogelijke werkingsmechanismen en 
gegevens over effectiviteit en toxiciteit van enkelvoudig gebruikt SSZ en MTX worden 
besproken. Het hoofdstuk besluit met een beschrijving van de fases van 
geneesmiddelontwikkeling en de relevantie ervan voor het onderzoek betreffende de 
combinatie van SSZ en MTX. 
Hoofdstuk 2 begint met de beschrijving van de ratio van het combineren van 
tweedelijns antireumatica. Zoals eerder genoemd, is het falen van enkelvoudige 
therapie de voornaamste. Andere redenen zijn het mogelijke synergisme, vermijden van 
dosis-gerelateerde bijwerkingen bij gebruik van combinaties in lage doseringen, het 
eerder vinden van een effectief middel en het behouden van residuele effecten van 
enkelvoudige therapie voorafgaande aan het combineren. Verschillende strategieën van 
combineren zijn denkbaar, grofweg verdeeld m het vanaf het begin van 
medicamenteuze therapie combineren van twee of meer middelen en het toevoegen van 
het volgende middel wanneer het voorafgaande niet effectief (meer) is. 
De resultaten van combinatie-therapie zijn zeer wisselend. Tot voor kort was er een 
gebrek aan goed ontworpen studies en was de indruk dat combinaties op zijn best een 
marginaal voordeel boden ten koste van toegenomen bijwerkingen. Recent zijn 
resultaten van enkele studies met een aanvaardbare methodologie (o.a. gebruik van zgn. 
controlegroepen) bekend geworden. De meeste hadden MTX als een van de 
componenten van de combinatie. Hoewel ook bij deze studies enkele vraagtekens 
omtrent de methodologie blijven, lijken enkele combinaties met MTX effectiever dan 
MTX alleen. 
Hoofdstuk 3 gaat over de mogelijke farmacokinetische interactie (beïnvloeden van 
eikaars opname, verdeling of uitscheiding) tussen MTX en SSZ, als een onderdeel van 
"fase 2"-onderzoek van de combinatie van beide. Tevens was de relatie tussen de 
farmacokinetiek en werking en bijwerking onderwerp van dit onderzoek. Bij vijftien 
patiënten met RA die onvoldoende reageerden op therapie met SSZ alleen, werden 
bloedspiegels van SSZ en stofwisselingsproducten ervan voorafgaande aan de 
combinatie met MTX gemeten. Daarna werd SSZ gestaakt en na 2 weken werd een 
curve van bloedspiegels van MTX van iedere patiënt bepaald. Na 4 weken 
combinatietherapie werden beide bepalingen herhaald. Er bleek geen 
farmacokinetische interactie te zijn tussen beide medicamenten. Er was slechts een 
zwakke en weinig consistente relatie tussen farmacokinetische bijzonderheden en 
werking, maar gezien het relatief kleine aantal onderzochte patiënten kan een toch 
по 
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aanwezige relatie verborgen zijn gebleven. Echter, ook andere studies vinden weinig of 
geen verband tussen (bij)werking en farmacokinetiek. 
De effecten van SSZ, MTX en de combinatie van beide op stoffen die een 
belangrijke rol spelen als "boodschappers" in het ontstekingsmechanisme: cytokines, 
gemeten in het bloed en de productie ervan in witte bloedcellen, worden weergegeven 
in Hoofdstuk 4. Dertig gezonde vrijwilligers werden vergeleken met 12 RA patiënten 
die alleen MTX, en 14 patiënten die de combinatie van MTX en SSZ kregen. RA 
patiënten hadden significant hogere spiegels van diverse cytokines en een hogere 
celproductie van deze stoffen vergeleken met gezonden. Afname van enkele van deze 
seinstoffen in het bloed en productie in cellen was alleen aantoonbaar bij de patiënten 
behandeld met de combinatie, in tegenstelling tot behandeling met MTX alleen. 
De biologische effecten (fase 2) van de combinatie van MTX en SSZ wordt 
beschreven in Hoofdstuk 5. Het bloedgehalte van het aminozuur (bouwsteen van 
eiwitten) homocysteine is een maat voor de stofwisseling van het foliumzuur-vitamine 
(vooral aanwezig in bladgroentes): hoe hoger des te minder werkzaam foliumzuur 
aanwezig. MTX is een middel dat lijkt te werken door interferentie met dit vitamine. 
Ook van SSZ wordt dit beweerd. MTX had een consistente verhoging van 
homocysteine tot gevolg, SSZ slechts een geringe, voorbijgaande toename. De 
combinatie gaf de grootste stijging. Patiënten met een genetisch bepaalde wijziging van 
een enzym dat betrokken is bij de stofwisseling van foliumzuur bleken hogere 
homocysteïnegehaltes te hebben, of te krijgen onder invloed van MTX als ze de 
genetische afwijking in milde mate hadden. Er bestond geen relatie tussen de 
werkzaamheid en het gehalte aan homocysteine, maar wel was er een samenhang 
tussen het optreden van maag-darm bijwerkingen en de stijging van homocysteine. 
Hoofdstuk 6 betreft eveneens fase 2 in de evaluatie van de combinatie van MTX en 
SSZ: de klinische beoordeling van de combinatie bij een beperkt aantal patiënten die 
onvoldoende respons hadden op SSZ alleen. Dit middel diende gedurende ten minste 6 
maanden en direct voorafgaande aan het onderzoek te zijn gegeven. Na een stopperiode 
van twee weken werd 40 patiënten (met actieve RA ondanks SSZ-doses tot 3 gram/dag, 
gemiddelde ziekteduur 5 jaar) een door het lot aangewezen therapie van ofwel MTX, 
ofwel MTX + SSZ. De dosering van MTX was initieel 7,5 mg/week, bij onvoldoende 
effectiviteit opgehoogd naar 15 mg/week. De dosering van SSZ was 2000 mg/dag. 
Zowel de patiënten als de onderzoeker waren op de hoogte van de aard van de therapie 
om de patiënten met de combinatie beter te kunnen evalueren, zowel wat betreft de 
toxiciteit als wat betreft de farmacokinetiek. De eerste 15 patiënten die de combinatie 
ontvingen, namen deel aan de farmacokinetische studie die al is beschreven in 
Hoofdstuk 3. Alle observaties werden verricht door één onderzoeker. De resultaten 
werden geanalyseerd door middel van eindpunt-analyse; alle patiënten, ook de 
uitvallers werden betrokken bij de analyse. De twee groepen waren vergelijkbaar bij de 
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start van de studie. Achtendertig patiënten volbrachten het onderzoek. Twee patiënten 
vielen uit, beide in de combinatiegroep, één t.g.v. het optreden van een lupusachtige 
ziekte, mogelijk veroorzaakt door de medicatie, en een ander door de noodzaak van een 
hartoperatie, niet gerelateerd met de medicatie. De gemiddelde afname van de 
ziekteactiviteitsscore was groter in de groep patiënten die de combinatie hadden dan in 
de groep met alleen MTX (respectievelijk -2,6 en -1,3); zowel statistisch als klinisch 
significant. Een vergelijkbaar resultaat was te zien bij de overige effectiviteits 
variabelen. Er was geen verschil in het optreden van toxiciteit: 11 patiënten die MTX 
alleen kregen en 8 patiënten in de combinatiegroep ervoeren bijwerkingen. 
De klinische toetsing, vervolgens uitgebreid naar patiënten met een vroege (net 
begonnen) RA, is verder beschreven in Hoofdstuk 7. Dit onderzoek was een groter, 
fase 3 onderzoek met 105 deelnemende patiënten. Alle patiënten hadden een vroege 
RA: de verschijnselen van gewrichtsontsteking duurden maximaal 12 maanden. Het 
doel van de studie was het vergelijken van de effectiviteit en veiligheid van SSZ, MTX 
of de combinatie van beide bij RA-patiënten die niet eerder met tweedelijns therapie 
behandeld waren. Het was een dubbelblinde, gerandomiseerde (therapiesoort door het 
lot bepaald) studie in één academisch centrum en vijf niet-academische 
reumatologische afdelingen. De patiënten moesten een actieve RA hebben en 
indicatoren van een slechte prognose: een aanwezige reumafactor en/of HLA DR 1/4 
positiviteit, om overbehandeling te voorkomen. De patiënten werden gerandomiseerd 
tussen en parallel behandeld met SSZ 2000 (maximaal 3000) mg/dag, MTX 7,5 
(maximaal 15) mg/week en de combinatie in dezelfde doseringen. Er waren geen 
statistisch significante verschillen tussen de 3 behandelingsgroepen bij de start van de 
behandeling. De gemiddelde verandering per patiënt van de ziekteactiviteitsscore (een 
oppervlakte onder de curve in tijd van de ziekteactiviteitsscore, gecorrigeerd voor de 
startwaarden) waren: SSZ: -1,6 (95% betrouwbaarheidsinterval (BI) -2,0 tot -1,2); 
MTX: -1,7 (BI -2,0 tot -1,4); combinatie: -1,9 (BI -2,2 tot -1,6). Het verschil tussen 
begin- en eindwaarden lieten hetzelfde patroon zien: een geringe trend tot een betere 
effectiviteit van de combinatie, maar geen statistisch of klinisch relevante verschillen. 
Het aantal patiënten uitgevallen wegens onvoldoende effectiviteit was 3 in de SSZ 
groep, 0 in de MTX-groep en 1 in de combinatiegroep. Het aantal patiënten met een 
dosisverhoging was 11 in de met SSZ behandelde patiënten, 11 in de MTX- en 7 in de 
combinatiegroep. Het voorkomen van bijwerkingen in het algemeen was groot en 
gelijkelijk verdeeld over de groepen. Misselijkheid kwam significant vaker voor in de 
combinatiegroep. Het aantal uitvallers door bijwerkingen was (niet significant) hoger 
bij SSZ behandelde patiënten, voornamelijk door het optreden van huiduitslag. 
Concluderend was er geen toegevoegde waarde van het combineren van de twee 
gebruikte geneesmiddelen. Er bleek slechts een geringe trend tot betere effectiviteit van 
de combinatie van SSZ en MTX. De betrouwbaarheidsintervallen sloten belangrijke 
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verschillen echter uit. Minder ernstige bijwerkingen kwamen vaker voor bij de met de 
combinatie behandelde patiënten. 
Bespreking 
De plaats van de combinatie van SSZ en MTX in het farmacologisch armamentarium 
tegen reumatoide artritis (RA) werd bestudeerd in de onderzoeken die in dit 
proefschrift beschreven zijn. De fases van geneesmiddelontwikkeling zijn gebruikt als 
een kader, hoewel de strikte tijdsvolgorde niet aangehouden werd. In een fase 2 studie 
betreffende verder voortgeschreden RA, die niet meer reageerde op behandeling met 
SSZ alleen, bleek de combinatie met MTX voordelen te bieden boven behandeling met 
MTX alleen, hetgeen de strategie van combineren door toevoegen ondersteunt. Bij 
vroege RA daarentegen, was er van zo'n voordeel geen sprake; wel was er enige 
toegenomen toxiciteit van de combinatie vergeleken met SSZ of MTX alleen. De 
meerderheid van de patiënten beschreven in Hoofdstuk 6 hadden initieel wel een 
gunstig effect van SSZ, hetgeen ze verloren hadden in de tijd voorafgaande aan het 
onderzoek. De effectiviteit van MTX was relatief bescheiden in dat onderzoek. De 
verschillen in de resultaten van de studie welke de "toevoegings"-strategie hanteerde 
(Hoofdstuk 6) en welke de parallelle benadering toepaste (Hoofdstuk 7) zouden 
verklaard kunnen worden door verschillende patiëntenpopulaties: verder gevorderde 
versus vroege RA. Verdere verklaring kan zijn dat MTX een secundaire resistentie 
tegen SSZ doorbreekt; mogelijkerwijs interfereert MTX met een mechanisme van 
induceerbare resistentie tegen SSZ. De manier waarop MTX dit bewerkstelligt is 
onduidelijk, maar misschien is de stofwisseling van foliumzuur hierbij betrokken 
(Hoofdstuk 5). Een andere verklaring van de discrepantie tussen de resultaten zou een 
soort "plafond"-effect in de vroege RA studie kunnen zijn: gegeven het grote aantal 
patiënten met een goede respons, is er slechts beperkte verdere verbetering mogelijk, en 
worden daardoor de verschillen gecomprimeerd. 
De gevonden verschillen tussen de combinatie en MTX alleen in Hoofdstuk 6 
kunnen niet verklaard worden door een interactie op farmacokinetisch niveau 
(Hoofdstuk 3). Hiermee in overeenstemming waren er ook geen consistente verbanden 
tussen farmacokinetische grootheden en klinische effecten. De vraag rijst dan ook 
welke farmacodynamische mechanismen de gevonden klinische verschillen kunnen 
verklaren. We bestudeerden daarom de mogelijke invloed van de twee geneesmiddelen 
op de plasma homocysteine concentratie, die veranderingen van foliumzuur afhankelijk 
celmetabolisme weerspiegelt, als de volgende stap in het onderzoek naar 
werkingsmechanisme van de combinatie. Hoewel geen invloed van SSZ alleen op 
plasma homocysteine werd gevonden, leek dit middel wel de invloed van MTX hierop 
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te vermeerderen. Een andere bevinding was de invloed van een bepaalde genetische 
verandering van het enzym methyleentetrahydrofolaat reductase dat betrokken is bij het 
foliumzuurmetabolisme op plasma homocysteine: een heterozygote mutatie (milde 
verandering) bleek te leiden tot hogere homocysteine spiegels na een jaar behandeling, 
zonder verschil tussen de drie behandelingsgroepen. Het is mogelijk dat de metabole 
omzetting van homocysteine tekort schiet als er een tekort ontstaat aan 
methyltetrahydrofolaat, nodig voor deze omzetting. Dit tekort is dan het gevolg van de 
belemmerde functie van het bovengenoemde enzym in mild veranderde vorm, door 
SSZ direct of indirect door MTX via beïnvloeding van het foliumzuurmetabolisme. Er 
was geen relatie tussen effectiviteit van de middelen en de veranderingen van plasma 
homocysteine, maar wel enige relatie met (gastrointestinale) bijwerkingen. 
Samengenomen met resultaten van andere onderzoeken waarin een relatie tussen 
homocysteine en toxiciteit ook werd gevonden, en de aanwijzingen dat foliumzuur en -
derivaten in lage dosering toxiciteit en niet effectiviteit beïnvloeden, lijkt het er op dat 
foliumzuur gerelateerde metabole processen die effectiviteit of toxiciteit bemiddelen, 
verschillend zijn. Homocysteine gerelateerde processen zijn dan mogelijk betrokken bij 
alleen toxiciteit. Dit zou verder getoetst kunnen worden door de omzetting van 
homocysteine naar methionine specifiek te beïnvloeden, door het geven van betaïne. 
Beginnend aan de andere kant van de keten van gebeurtenissen die het 
werkingsmechanisme vertegenwoordigt, werd de invloed van de combinatie op 
onstekingsmediatoren bestudeerd (Hoofdstuk 4). We onderzochten bloedspiegels van 
cytokines en productie van cytokines door witte bloedcellen. Er waren enkele 
aanwijzingen dat de combinatie van SSZ en MTX toegevoegde invloed had op 
oplosbare TNF receptoren en cellulaire productie van II-Iß en 111 receptorantagonist. 
Of deze veranderingen werkelijk (enkele) van de klinische verschillen verklaren is nog 
onbewezen omdat een oorzakelijke relatie tussen deze farmacodynamische verschillen 
en klinische effecten nog niet is aangetoond. 
Kortom, de combinatie van MTX en SSZ kan niet worden aangeraden in een parallelle 
strategie bij beginnende reumatoide artritis, maar lijkt mogelijk wel voordeel te bieden 
bij de behandeling van verder gevorderde RA als SSZ onvoldoende soelaas biedt. 
Toekomstige studies betreffende de combinatie van SSZ en MTX moeten gericht 
zijn op het gebruik bij patiënten waarbij beide individuele middelen onvoldoende effect 
hadden. Het gebruik van de combinatie bij falen van SSZ zonder voorafgaand gebruik 
van MTX en vice versa moet verder klinisch bevestigd worden. De invloed van SSZ en 
MTX alleen en in combinatie op het foliumzuurmetabolisme, in relatie tot bij 
ontsteking actieve stoffen (bijvoorbeeld polyamines, adenosine en uiteindelijk 
moleculen zoals cytokines), zou uitgebreider onderzocht dienen te worden. Dit kan de 
mogelijk verschillende processen die leiden naar effectiviteit en toxiciteit verklaren. 
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Monique Helsen en andere medewerkers van het laboratorium reumatologie voor het 
bewerken van het spijtbloed. 
Marion Janssen en Marianne Verhoeven waren van groot belang om de combinatie 
van werk en onderzoek mogelijk te maken. 
De desbetreffenden van Reumatologen Oost-Nederland voor de gelegenheid om in 
hun kliniek bij hun patiënten het onderzoek te verrichten. 
Secretaresses/doktersassistenten van de deelnemende reumatologie afdelingen, jullie 
steun hield mij op de been en op de weg. 
Afdeling reumatologie AZN en St. Maartenskliniek voor de gastvrijheid voor mij en 
"mijn" patiënten die deelnamen aan het onderzoek van bloedspiegels. 
De medewerkers van het laboratorium kindergeneeskunde (met name Dinny van 
Oppenraaij -Immerzeel, Belinda Giesendorf, Stephanie Vloet, Inge Konijnenberg, en 
het hoofd, prof. Trijbels) en de Universitaire Transfusiedienst. 
De medewerkers van Pharmacia Nederland, т.п. Clemens van Ede, en Pharmacia 
Zweden: Ulla Bengtsson en Marie Lindahl, thank you for the efficient and pleasant 
communication, in spite of digital dykes. 
Miriam Hassink voor de hulp bij de laatste loodjes. 
Mijn huidige en vroegere collega's, voor hun samenwerking en steun op meerdere 
wijzen. 
En "thuis" vanzelfsprekend. 
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Stellingen. 
1. 1 + 1^2 . (dit proefschrift) 
2. "Het kind met het badwater weggooien" geldt ook voor het 
stoppen van sulfasalazine indien dit niet meer voldoende 
effectief is. (dit proefschrift) 
3. Ondanks grote interindividuele verschillen voorspelt 
farmacokinetiek klinische verschijnselen slecht, (dit proefschrift) 
4. Onderzoek naar geneesmiddelen doen in meerdere klinieken 
leidt tot onverwachte bijwerkingen, zoals bekeuringen. 
(eigen waarneming) 
5. Sulfasalazine is geen effectieve folaatantagonist. 
(dit proefschrift) 
6. Bijwerkingen van methotrexaat ontstaan door gestoorde 
remethylering van homocysteine, (dit proefschrift) 
7. De wet van Murphy: "alles wat fout kan gaan, zal ook fout 
gaan", klopt niet. (dit proefschrift) 
8. Van ziek zijn wordt een dokter beter. 
(naar H.S. Waxman. "The Patient as Physician". Annals of 
Internal Medicine 1997;126:656-7) 
9. Zonder goede statistiek is veel onderzoek kansloos. 
10. De beschaving van een maatschappij wordt bepaald door de 
mate van collectieve zorg voor haar kwetsbaren. 
11. Het is goed dat stellingen op een los blaadje dienen te staan. 



